

US00RE49347E

(19) **United States**
 (12) **Reissued Patent**
Knopf et al.

(10) **Patent Number: US RE49,347 E**
 (45) **Date of Reissued Patent: Dec. 27, 2022**

(54) **MAMMALIAN EXPRESSION VECTOR**

(71) Applicant: **NOVARTIS AG**, Basel (CH)

(72) Inventors: **Hans-Peter Knopf**, Schallstadt (DE);
Burkhard Wilms, Weil am Rhein (DE)

(73) Assignee: **Novartis AG**, Basel (CH)

(21) Appl. No.: **16/110,010**

(22) Filed: **Aug. 23, 2018**

Related U.S. Patent Documents

Reissue of:

(64) Patent No.: **9,422,574**
 Issued: **Aug. 23, 2016**
 Appl. No.: **13/482,117**
 Filed: **May 29, 2012**

U.S. Applications:

(63) Continuation of application No. 12/808,798, filed as application No. PCT/EP2008/067947 on Dec. 18, 2008, now abandoned.

(30) **Foreign Application Priority Data**

Dec. 21, 2007 (EP) 07150339

(51) **Int. Cl.**
C12N 15/85 (2006.01)
 (52) **U.S. Cl.**
 CPC **C12N 15/85** (2013.01)
 (58) **Field of Classification Search**
 CPC **C12N 15/85**
 See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,017,478 A	5/1991	Cashion et al.
2001/0024807 A1	9/2001	Innis et al.
2004/0148647 A1	7/2004	Enenkel et al.
2005/0153394 A1	7/2005	Black
2006/0024650 A1	2/2006	Epstein
2006/0246540 A1	11/2006	Ashkenazi

FOREIGN PATENT DOCUMENTS

EP	0555203 A4	3/1992
EP	0555203 B1	8/1993
EP	1293564 A1	3/2003
RU	2177999 C2	1/2002
WO	1996/009375 A1	3/1996
WO	01/04306 A1	1/2001
WO	2001/04306 A1	1/2001
WO	2004/050879 A1	6/2004
WO	2004/050879 A1	7/2004

OTHER PUBLICATIONS

Makrides. Protein Expression and Purification 17, 183-202 (1999).*
 Grillari. Journal of Biotechnology 87, pp. 59-65 (2001).*
 Barnett et al., "Antibody production in Chinese hamster ovary cells using an impaired selectable marker," ACS Symp. Ser., vol. 604:27-40 (1995).

Bebbington et al., "High level expression of a recombinant antibody from myeloma cells using a glutamine synthetase gene as an amplifiable selectable marker," Biotechnology, vol. 10:169-175 (1992).

Eaton et al., "Construction and characterization of an active factor VIII variant lacking the central one-third of the molecule," Biochemistry, vol. 25(26):8343-8347 (1986).

Hartmann et al., "Two dominant-acting selectable markers for gene transfer studies in mammalian cells", PNAS, vol. 85:8047-8051 (1988).

Levit et al., "Definition of an efficient synthetic poly(A) site", Genes and Dev, vol. 3(7):1019-1025 (1989).

Lin et al., "Expression efficiency of the human thrombomodulin-encoding gene in various vector and host systems," Gene, Elsevier, vol. 147(2):287-292 (1994).

Neuberger: "Expression and regulation of immunoglobulin heavy chain gene transfected into lymphoid cells", EMBO J., vol. 2(8):1373-1378 (1983).

Sautter et al., "Selection of high-producing CHO cells using NPT selection marker with reduced enzyme activity," Bioengineering, vol. 89(5):530-538 (2005).

Simonsen et al., "Isolation and expression of an altered mouse dehydrofolate reductase cDNA", PNAS, vol. 80:2495-2499 (1983).

Subramani et al., "Expression of the mouse dihydrofolate reductase complementary deoxyribonucleic acid in simian virus 40 vectors", Mol. Cell Biol., vol. 1(9):854-864 (1981).

Trill et al., "Production of monoclonal antibodies in COS and CHO cells," Current Opinion in Biotechnology, vol. 6:553-560 (1995).

Vieira et al., "The pUC plasmids an M13mp7-derived system for insertion mutagenesis and sequence with synthetic universal primers," Gene, vol. 19(3):259-268 (1982).

Wurm, "Production of recombinant protein therapeutics in cultivated mammalian cells," Nature Biotechnology, vol. 22 (11):1393-1398 (2004).

(Continued)

Primary Examiner — Padmashri Ponnaluri

(74) *Attorney, Agent, or Firm* — Nelson Mullins Riley & Scarborough LLP; Jane E. Remillard, Esq.; Christopher L. Frank

(57) **ABSTRACT**

The invention provides vector nucleic acid for expressing at least one polypeptide of interest in a mammalian cell, comprising

- (a) at least one expression cassette (POI) for expressing a polypeptide of interest;
- (b) an expression cassette (MSM) comprising a mammalian selectable marker gene;
- (c) an expression cassette (MASM) comprising a mammalian amplifiable, selectable marker gene;

wherein the expression cassette (POI) is flanked 5' by the expression cassette (MASM), the expression cassette (MSM) is located 3' from the expression cassette (POI) and wherein the expression cassettes (MASM), (POI) and (MSM) are arranged in the same 5' to 3' orientation.

Also provided are host cells, comprising said vector and methods for producing a polypeptide using respective host cells.

27 Claims, 2 Drawing Sheets

Specification includes a Sequence Listing.

(56)

References Cited

OTHER PUBLICATIONS

Reff et al.; Depletion of B Cells In Vivo by a Chimeric Mouse Human Monoclonal Antibody to CD20; *Blood*; vol. 83, No. 2; pp. 435-445; Jan. 15, 1994.*

Reff et al: "Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20", *Blood*; 83 (2):435-445 (1994).

Grillari et al: "Analysis of alterations in gene expression after amplification of recombinant genes in CHO cells", *J. Biotechnol.* 87:59-65 (2001).

Hartmann et al: "Two dominant-acting selectable markers for gene transfer studies in mammalian cells", *PNAS*, 85:8047-8051 (1988).

Levit et al: "Definition of an efficient synthetic poly(A) site", *Genes and Dev.* 3(7):1019-1025 (1989).

Makrides: "Components of vectors for gene transfer and expression", *Protein Expression and Purification* 17:183-202 (1999).

Michael Wigler et al: "Transformation of mammalian cells with genes from procaryotes and eucaryotes", *Cell*, vol. 16, pp. 777-785, Apr. 1979.

* cited by examiner





Fig. 1

Fig. 2



MAMMALIAN EXPRESSION VECTOR

Matter enclosed in heavy brackets [] appears in the original patent but forms no part of this reissue specification; matter printed in italics indicates the additions made by reissue; a claim printed with strikethrough indicates that the claim was canceled, disclaimed, or held invalid by a prior post-patent action or proceeding.

This is a continuation of application Ser. No. 12/808,798 filed on Jun. 17, 2010, which is a National Stage of International Application No. PCT/EP2008/067947 filed on Dec. 18, 2008, which claims priority under 35 U.S.C. §119 to EP Application Serial No. 07150339.5 filed Dec. 21, 2007, each of which applications in its entirety is herein incorporated by reference.

The present invention pertains to a mammalian expression vector for expressing a polypeptide of interest as well as to methods for expressing a polypeptide of interest in a mammalian host cell by using a respective vector and host cells comprising said vector.

The ability to clone and express recombinant peptides and proteins in large amounts has become increasingly important in the recent years. The ability to purify high levels of proteins is important in the human pharmaceutical and biotechnological field, for example for producing protein pharmaceuticals as well as in the basic research setting, for example for crystallizing proteins to allow the determination of the three dimensional structure. Proteins that are otherwise difficult to obtain in quantity can be over-expressed in a host cell and subsequently isolated and purified.

The choice of an expression system for the production of recombinant proteins depends on many factors, including cell growth characteristics, expression levels, intracellular and extracellular expression, post-translational modifications and biological activity of the protein of interest, as well as regulatory issues and economic considerations in the production of therapeutic proteins. Key advantages of mammalian cells over other expression systems such as bacteria or yeast are the ability to carry out proper protein folding, complex N-linked glycosylation and authentic O-linked glycosylation, as well as a broad spectrum of other post-translational modifications. Due to the described advantages, mammalian cells are currently the expression system of choice for producing complex therapeutic proteins such as monoclonal antibodies. The first step in generating a recombinant cell line is the construction of an expression vector. The expression vector is the key element for driving the expression of the heterologous gene in the host cell and for providing selection markers for generating the recombinant cell line. The essential elements of mammalian expression vectors usually include a constitutive or inducible promoter capable of robust transcriptional activity; optimized mRNA processing and translational signals that usually include a Kozak sequence, a translation termination codon, mRNA cleavage and polyadenylation signals, as well as mRNA splicing signals; a transcription terminator; selection markers for the preparation of stable cell lines and for gene amplification; a prokaryotic origin of replication and selection markers for vector propagation in bacteria.

In recent years the focus of development was concentrating on the design of improved vectors for gene expression in mammalian cells. In spite of the plethora of available vectors, however, robust polypeptide/protein production in mammalian cells is still challenging. Several factors can

influence recombinant expression in mammalian cells, including promoter strength, the context of the 5' untranslated and the translation initiation region, the efficiency of the 3' untranslated region, to polyadenylate and terminate transcription, the insertion site of the randomly integrated recombinant gene in the host chromosome, and the number of integrated copies of the gene that is being expressed. Increases in gene copy number are most commonly achieved by gene amplification using cells lines deficient in an enzyme such as dihydrofolate reductase (DHFR) or glutamine synthetase (GS) in conjunction with expression vectors containing genes encoding these enzymes and agents such as methotrexate (MTX), which inhibits DHFR, and methionine sulfoxamine (MSX) which inhibits GS. Using expression vectors containing the recombinant gene under control of a strong promoter and genes encoding DHFR or GS, DHFR⁺ or GS⁺ transfectants, respectively, are first obtained and gene amplification is then achieved by growing the transfectants in progressively increasing concentrations of MTX or MSX.

It is the object of the present invention, to provide an improved expression vector as well as an expression system for expressing a polypeptide of interest in a mammalian cell.

Accordingly, a vector nucleic acid for expressing at least one polypeptide of interest in a mammalian cell is provided, comprising

- (a) at least one expression cassette (POI) for expressing a polypeptide of interest;
 - (b) an expression cassette (MSM) comprising a mammalian selectable marker gene;
 - (c) an expression cassette (MASM) comprising a mammalian amplifiable, selectable marker gene;
- wherein the expression cassette (POI) is flanked 5' by the expression cassette (MASM), the expression cassette (MSM) is located 3' from the expression cassette (POI) and wherein the expression cassettes (MASM), (POI) and (MSM) are arranged in the same 5' to 3' orientation.

A "vector nucleic acid" according to the present invention is a polynucleotide that carries at least one foreign nucleic acid fragment. A vector nucleic acid functions like a "molecular carrier", delivering fragments of nucleic acids respectively polynucleotides into a host cell. It comprises at least one expression cassette comprising regulatory and coding sequences. An expression cassette allows the proper expression of an incorporated polynucleotide. The expression cassettes decisive for the present invention will be subsequently described in further detail. Foreign polynucleotides e.g. encoding the polypeptide of interest may be inserted into the expression cassettes of the vector nucleic acid in order to be expressed. The vector nucleic acid according to the present invention may be present in circular or linearized form. Said site may e.g. be a multiple cloning site (MCS).

The expression cassette (POI) defines the expression cassette for expressing a polypeptide of interest. Said expression cassette (POI) either comprises the polynucleotide encoding the polypeptide of interest or comprises a site suitable for inserting a respective polynucleotide encoding the polypeptide of interest.

A "polypeptide" refers to a molecule comprising a polymer of amino acids linked together by a peptide bond(s). Polypeptides include polypeptides of any length, including proteins (for example, having more than 50 amino acids) and peptides (for example, having 2-49 amino acids). Polypeptides include proteins and/or peptides of any activity or bioactivity. Suitable examples are outlined below.

The expression cassette (MSM) defines the expression cassette comprising a mammalian selectable marker gene. Mammalian selectable marker genes allow the selection of mammalian host cells comprising said genes and thus of mammalian host cells comprising the vector. Suitable examples are described in detail below.

The expression cassette (MASM) defines the expression cassette comprising a mammalian amplifiable, selectable marker gene. Mammalian, amplifiable, selectable marker genes allow selection of vector-containing mammalian host cells as well as gene amplification. Suitable examples are described in detail below.

The terms "5'" and "3'" is a convention used to describe features of a nucleic acid sequence related to either the position of genetic elements and/or the direction of events (5' to 3'), such as e.g. transcription by RNA polymerase or translation by the ribosome which proceeds in 5' to 3' direction. Synonyms are upstream (5') and downstream (3'). Conventionally, DNA sequences, gene maps, vector cards and RNA sequences are drawn with 5' to 3' from left to right or the 5' to 3' direction is indicated with arrows, wherein the arrowhead points in the 3' direction. Accordingly, 5' (upstream) indicates genetic elements positioned towards the left hand side, and 3' (downstream) indicates genetic elements positioned towards the right hand side, when following this convention.

The arrangement and orientation of the expression cassettes present in the vector of the invention is important. According to the teachings of the present invention, the expression cassette (POI) is flanked 5' by the expression cassette (MASM). Accordingly, the expression cassette (MASM) is located 5' adjacent to the expression cassette (POI) and in close proximity thereto. Of course, vector backbone sequences may separate the expression cassettes (MASM) and (POI). However, preferably, no other expression cassette is located between the expression cassette (MASM) and the expression cassette (POI). The expression cassette (MSM) is located 3' from the expression cassette (POI). Further expression cassettes may be inserted between the expression cassettes (POI) and (MSM), such as e.g. an additional expression cassette (POI') for expressing an additional polypeptide of interest (described in further detail below). The expression cassettes (MASM), (POI) and (MSM) are all arranged in the same 5' to 3' orientation. The inventors found, that this particular vector nucleic acid configuration allows the fast generation of high yielding cell lines.

According to one alternative, the expression cassette (POI) does not comprise the polynucleotide encoding the polypeptide of interest. Thus, an expression vector with an "empty" expression cassette (POI) is provided. However, said polynucleotide encoding the polypeptide of interest can be incorporated into the expression cassette (POI) by using appropriate cloning methods, for example by using restriction enzymes in order to insert the polynucleotide encoding the polypeptide of interest into the expression cassette (POI). For this purpose the expression cassette (POI) may comprise e.g. a multiple cloning site (MCS) which can e.g. be used in all reading frames. Suitable MCS sites are described in detail below. A respective "empty" vector nucleic acid can e.g. be provided to customers, which then insert their specific polynucleotide of interest to be expressed into the expression cassette (POI). The expression cassette (POI) may also comprise a replacement polynucleotide or a stuffer nucleic acid sequence, which can be excised and replaced by the polynucleotide encoding the polypeptide of interest. The present invention also provides

a vector nucleic acid as described above, comprising an expression cassette (POI) comprising the polynucleotide encoding the polypeptide of interest. This embodiment pertains basically to the final expression vector nucleic acid that is transfected for expression into the host cell.

A polynucleotide is a polymer of nucleotides which are usually linked from one deoxyribose or ribose to another. The term "polynucleotide" does not comprise any size restrictions and also encompasses polynucleotides comprising modifications, in particular modified nucleotides.

According to one embodiment, the vector nucleic acid is circular and the expression cassette (MSM) is arranged 3' of the expression cassette (POI) and the expression cassette (MASM) is arranged 3' of the expression cassette (MSM).

As an alternative description of a circular vector according to the teachings of the present invention is a circular vector nucleic acid for expressing at least one polypeptide of interest in a mammalian cell, comprising

- (a) at least one expression cassette (POI) for expressing a polypeptide of interest;
- (b) an expression cassette (MSM) comprising a mammalian selectable marker gene;
- (c) an expression cassette (MASM) comprising a mammalian amplifiable, selectable marker gene;

wherein the expression cassette (MSM) is arranged 3' of the expression cassette (POI) and the expression cassette (MASM) is arranged 3' of the expression cassette (MSM) and wherein the expression cassettes (MASM), (POI) and (MSM) are arranged in the same 5' to 3' orientation.

The vector nucleic acid can be transfected into the host cell in its circular form. Supercoiled vector molecules usually will be converted into linear molecules within the nucleus due to the activity of endo- and exonucleases. However, linearization of the vector nucleic acid before transfection often improves the efficiency of a stable transfection. This also as the point of linearization may be controlled if the vector is linearized prior to transfection.

Hence, according to one embodiment of the present invention the expression vector comprises a predefined restriction site, which can be used for linearization of the vector nucleic acid prior to transfection. Intelligent placement of said linearization restriction site is important, because said restriction site determines where the vector nucleic acid is opened/linearized and thus determines the order/arrangement of the expression cassettes when the construct is integrated into the genome of the mammalian cell.

Accordingly, the vector nucleic acid may comprise a linearization restriction site for linearizing the vector, wherein said linearization restriction site is located between the expression cassettes (MSM) and (MASM). Preferably, said linearization restriction site is unique and is only once present in the expression vector nucleic acid. E.g. a linearization restriction site can be used that is recognized by a restriction enzyme having a low cutting frequency in order to patronize that the vector is only cleaved at the linearization restriction site but not (or only rarely) e.g. within the expression cassette(s) or the vector backbone. This can e.g. be encouraged by providing a restriction site for a restriction enzyme having a recognition sequence of more than six base pairs or which recognizes sequences that are under-represented in chromosomal DNA. A suitable example is the *Swa*I enzyme and the vector may therefore incorporate a *Swa*I recognition site as unique linearization restriction site. In case said linearization restriction site is present more than once in the vector nucleic acid sequence (including the polynucleotides encoding the polypeptide of interest), or in

case a restriction enzyme is used which cuts several times in the vector nucleic acid sequence, it is also within the scope of the present invention to e.g. alter/mutate the restriction sites besides the linearization restriction site which is located between the expression cassettes (MSM) and (MASM), in order to eliminate those additional restriction sites and to obtain a unique or at least rare linearization restriction site.

In case the vector is used as a standard expression vector intended e.g. as a tool for the expression of several different polypeptides, it is advantageous to provide a linearization restriction site comprising multiple recognition sites for enzymes having a low cutting frequency. The restriction enzymes chosen for linearization should preferably not cut within the expression cassettes for the selectable markers or other vector backbone sequences in order to ensure that the enzyme cuts only once for proper linearization of the vector. By providing a linearization restriction site comprising multiple recognition sites for restriction enzymes having a low cutting frequency, the user may choose a suitable restriction enzyme for linearization from the provided options in order to securely avoid restriction within the polynucleotide encoding the polypeptide of interest. However, as is outlined above, additional restriction sites may be mutated or a partial restriction digest could be performed.

Placing the linearization restriction site between the expression cassette (MSM) and the expression cassette (MASM) has the effect that the expression cassette (POI) (and further expression cassettes for expressing the polypeptides of interest—if present) is flanked 5' by the expression cassette (MASM). The expression cassette (MSM) is located 3' of the expression cassette (POI) upon linearization. Thereby, the expression cassettes (MSM) and (MASM) are separated upon linearization of the circular vector nucleic acid. If an expression cassette (PSM) for a bacterial selection marker is present (see below), the linearization restriction site is preferably placed between the expression cassettes (PSM) and (MASM). This has the effect that the bacterial selection marker gene is 3' and thus “outside” of the “mammalian” parts of the linearized vector nucleic acid. This arrangement is favorable since bacterial genes are presumably not advantageous for mammalian expression as bacterial sequences may lead to increased methylation or other silencing effects in the mammalian cells.

Non-limiting examples for mammalian selectable marker genes that can be comprised in the expression cassette (MSM) include antibiotic resistance genes e.g. conferring resistance to G418; hygromycin (hyg or hph, commercially available from Life Technologies, Inc. Gaithersboro, Md.); neomycin (neo, commercially available from Life Technologies, Inc. Gaithersboro, Md.); zeocin (Sh Ble, commercially available from Pharmingen, San Diego Calif.); puromycin (pac, puromycin-N-acetyl-transferase, available from Clontech, Palo Alto Calif.), ouabain (oua, available from Pharmingen) and blasticidin (available from Invitrogen). Respective mammalian selectable marker genes are well known and allow the selection of mammalian host cells comprising said genes and thus of host cells comprising the vector. The term “gene” as used herein also refers to a natural or synthetic polynucleotide encoding a functional variant of the selectable marker providing the intended resistance. Hence, also truncated or mutated versions of a wild type gene or synthetic polynucleotides are encompassed as long as they provide the intended resistance. According to a preferred embodiment, said expression cassette (MSM) comprises a gene encoding an enzymatically functional neomycin phosphotransferase (I or II). This embodiment works well in combination with the use of a

gene encoding an enzymatically functional DHFR as an amplifiable selectable marker gene.

Amplifiable, selectable mammalian marker genes allow selection of vector-containing mammalian host cells as well as gene amplification. A non-limiting example for an amplifiable, selectable mammalian marker gene is the dihydrofolate reductase (DHFR) gene. Other systems currently in use are among others the glutamine synthetase (gs) system (Bebbington et al., 1992) and the histidinol driven selection system (Hartmann and Mulligan, 1988). These amplifiable markers are also selectable markers and can thus be used to select those cells that obtained the vector. DHFR and glutamine synthetase provide good results. In both cases selection usually occurs in the absence of the appropriate metabolite (hypoxanthine and thymidine in case of DHFR, glutamine in the case of GS), preventing growth of non-transformed cells. With amplifiable systems such as the DHFR system, expression of a recombinant protein can be increased by exposing the cells to certain agents promoting gene amplification such as antifolates (e.g. methotrexate (MTX)) in case of the DHFR system. A suitable inhibitor for GS promoting gene amplification is methionine sulphoximine (MSX). Exposure to MSX also results in gene amplification. According to one embodiment, said expression cassette (MASM) comprises a gene encoding an enzymatically functional glutamine synthetase (GS) or a dihydrofolate reductase (DHFR).

According to one embodiment, said expression cassette (MSM) comprises a gene encoding an enzymatically functional neomycin phosphotransferase and said expression cassette (MASM) comprises a gene encoding an enzymatically functional dihydrofolate reductase (DHFR).

The vector may comprise at least one additional expression cassette (POI') for expressing an additional polypeptide of interest. Said additional expression cassette (POI') is located between the expression cassette (POI) and the expression cassette (MSM). Said expression cassette (POI') is arranged in the same 5' to 3' orientation as the expression cassettes (POI) and (MSM). According to one embodiment, it comprises the polynucleotide encoding the additional polypeptide of interest.

Accordingly, the vector nucleic acid according to the present invention can comprise more than one expression cassette for expressing polypeptides of interest. Therefore, it is also possible that several expression cassettes ((POI), (POI'), (POI'') etc.) for expressing different polypeptides of interest are arranged in the expression vector nucleic acid according to the present invention. These expression cassettes are flanked 5' by the expression cassette (MASM) and 3' by the expression cassette (MSM). Hence, the present invention also provides a vector nucleic acid comprising more than one expression cassette encoding e.g. subunits of dimeric or higher order multimeric proteins. Expression cassettes encoding different subunits of a multimeric protein, each incorporated in a different expression cassette can be placed adjacent to each other. For multimeric proteins encoded by at least two distinct genes (for instance, immunoglobulin light and heavy chains or functional fragments thereof such as at least the variable regions of the immunoglobulin light and heavy chains), the polynucleotides encoding the desired subunits of the polypeptide of interest are inserted in the expression cassettes (POI) and (POI'). A respective embodiment using at least two expression cassettes (POI) and (POI') for expressing polypeptides of interest is particularly advantageous for expressing immunoglobulin molecules such as antibodies or functional fragments thereof. Accordingly, a vector nucleic acid is

provided for expressing an immunoglobulin molecule comprising in each expression cassette (POI) and (POI') a polynucleotide encoding either a light or a heavy chain of an immunoglobulin molecule or fragments thereof, wherein each expression cassette (POI) and (POI') comprises one of said polynucleotides. Accordingly, the expression cassette (POI) can either comprise the polynucleotide for expressing the light chain, or the polynucleotide for expressing the heavy chain of the immunoglobulin molecule.

According to one preferred embodiment, the expression cassette (POI) comprises the polynucleotide encoding at least part of the light chain of said immunoglobulin molecule or a functional fragment thereof and the expression cassette (POI') comprises a polynucleotide encoding at least part of the heavy chain of said immunoglobulin molecule or a functional fragment thereof. To arrange the expression cassette for the light chain 5' to the expression cassette of the heavy chain proved to be beneficial regarding the expression rate of the immunoglobulin molecules. According to one embodiment, the expression vector nucleic acid is designed such, that the expression cassette(s) already comprises a polynucleotide encoding at least part of the constant regions of an immunoglobulin molecule. The polynucleotide fragments encoding the variable parts of the immunoglobulin molecules can then be inserted by the user/customer into the expression cassettes by using appropriate cloning strategies in order to obtain the final expression vector.

The expression cassettes present in the expression vector according to the present invention are designed such that they allow the expression of the incorporated polynucleotides/genes in mammalian cells. For this purpose the expression cassettes usually comprise the necessary regulatory sequences, such as a promoter and/or a transcription termination sequence such as a poly A site.

Vectors used for expressing polypeptides of interest usually contain transcriptional control elements suitable to drive transcription such as e.g. promoters, enhancers, polyadenylation signals, transcription pausing or termination signals as elements of an expression cassette. For proper expression of the polypeptides, suitable translational control elements are preferably included in the vector, such as e.g. 5' untranslated regions leading to 5' cap structures suitable for recruiting ribosomes and stop codons to terminate the translation process. In particular, the polynucleotide serving as the selectable marker genes as well as the polynucleotide encoding the polypeptide of interest can be transcribed under the control of transcription elements present in appropriate promoters. The resultant transcripts of the selectable marker genes and that of the polypeptide of interest harbour functional translation elements that facilitate substantial levels of protein expression (i.e. translation) and proper translation termination. A functional expression unit, capable of properly driving the expression of an incorporated polynucleotide is also referred to as an "expression cassette" herein. Preferably, it comprises a 3' UTR region.

Accordingly, vector nucleic acids are provided wherein the expression cassettes comprise at least one promoter and/or promoter/enhancer element. Although the physical boundaries between these two control elements are not always clear, the term "promoter" usually refers to a site on the nucleic acid molecule to which an RNA polymerase and/or any associated factors binds and at which transcription is initiated. Enhancers potentiate promoter activity, temporarily as well as spatially. Many promoters are transcriptionally active in a wide range of cell types. Promoters can be divided in two classes, those that function constitutively and those that are regulated by induction or derepres-

sion. Promoters used for high-level production of proteins in mammalian cells should be strong and preferably active in a wide range of cell types to permit a qualitative and quantitative evaluation of the recombinant polypeptide. The promoter can be selected from the group consisting of an SV40 promoter, a CMV promoter, an EF1alpha promoter, a RSV promoter, a BROAD3 promoter, a murine rosa 26 promoter, a pCEFL promoter and a β -actin promoter. Strong constitutive promoters which drive expression in many cell types include but are not limited to the adenovirus major late promoter, the human cytomegalovirus immediate early promoter, the SV40 and Rous Sarcoma virus promoter, and the murine 3-phosphoglycerate kinase promoter and EF1a. Good results are achieved with the expression vector of the present invention when the promoter and/or enhancer is either obtained from CMV and/or SV40.

According to one embodiment, the expression cassette(s) for expressing the polypeptide(s) of interest comprise(s) a stronger promoter and/or enhancer than the expression cassettes for expressing the selectable markers. This arrangement has the effect that more transcript for the polypeptide of interest is generated than for the selection markers. It is advantageous that the production of the polypeptide of interest which is secreted is dominant over the production of the selection markers, since the individual cell capacity for producing heterologous proteins is not unlimited and should thus be focused to the polypeptide of interest.

According to one embodiment, the expression cassettes (POI) and (POI') (if present) which is/are used for expressing the polypeptide of interest comprise a CMV promoter/enhancer. Specific examples are described in detail below. The expression cassettes (MSM) and (MASM), which preferably express the DHFR and the neomycin marker genes, comprise a SV40 promoter or a SV40 promoter/enhancer. The CMV promoter is known to be one of the strongest promoters available for mammalian expression and leads to a very good expression rate. It is considered to give significantly more transcript than the SV40 promoter.

Furthermore, the expression cassettes may comprise an appropriate transcription termination site. This, as continued transcription from an upstream promoter through a second transcription unit may inhibit the function of the downstream promoter, a phenomenon known as promoter occlusion or transcriptional interference. This event has been described in both prokaryotes and eukaryotes. The proper placement of transcriptional termination signals between two transcription units can prevent promoter occlusion. Transcription termination sites are well characterized and their incorporation in expression vectors has been shown to have multiple beneficial effects on gene expression.

Most eukaryotic nascent mRNAs possess a poly A tail at their 3' end which is added during a complex process that involves cleavage of the primary transcript and a coupled polyadenylation reaction. The polyA tail is advantageous for mRNA stability and transferability. Hence, the expression cassettes of the vector according to the present invention usually comprise a polyadenylation site. There are several efficient polyA signals that can be used in mammalian expression vectors, including those derived from bovine growth hormone (bgh), mouse beta-globin, the SV40 early transcription unit and the Herpes simplex virus thymidine kinase gene. However, also synthetic polyadenylation sites are known (see e.g. the pCl-neo expression vector of Promega which is based on Levitt et al, 1989, Genes Dev. 3, (7): 1019-1025). The polyadenylation site can be selected from the group consisting of SV40polyA site, such as the SV40 late and early poly-A site (see e.g. plasmid pSV2-DHFR as

described in Subramani et al, 1981, Mol. Cell. Biol. 854-864), a synthetic polyA site (see e.g. the pCl-neo expression vector of Promega which is based on Levitt et al, 1989, Genes Dev. 3, (7): 1019-1025) and a bgh polyA site (bovine growth hormone).

The expression cassettes may comprise an enhancer (see above) and/or an intron. According to one embodiment, the expression cassette(s) for expressing the polypeptide of interest comprise an intron. Most genes from higher eukaryotes contain introns which are removed during RNA processing. It is found, that genomic constructs are expressed more efficiently in transgenic systems than identical constructs lacking introns. Usually, introns are placed at the 5' end of the open reading frame. Accordingly, an intron may be comprised in the expression cassette(s) for expressing the polypeptide(s) of interest in order to increase the expression rate. Said intron may be located between the promoter and or promoter/enhancer element(s) and the 5' end of the open reading frame of the polypeptide to be expressed. Hence, a vector nucleic acid is provided, wherein at least the expression cassette (POI) comprises an intron which is arranged between the promoter and the start codon of the polynucleotide for expressing the polypeptide of interest. Several suitable introns are known in the state of the art that can be used in conjunction with the present invention.

According to one embodiment, the intron used in the expression cassettes for expressing the polypeptides of interest, is a synthetic intron such as the SIS or the RK intron. The RK intron is a strong synthetic intron which is preferably placed before the ATG startcodon of the gene of interest. The RK intron consists of the intron donor splice site of the CMV promoter and the acceptor splice site of the mouse IgG Heavy chain variable region (see e.g. Eaton et al., 1986, Biochemistry 25, 8343-8347, Neuberger et al., 1983, EMBO J. 2(8), 1373-1378; it can be obtained from the pRK-5 vector (BD PharMingen)).

Furthermore, it is surprisingly found that the placement of an intron at the 3' end of the open reading frame of the DHFR gene has advantageous effects on the expression/amplification rate of the construct. The intron used in the DHFR expression cassette is leading to a smaller, non functional variant of the DHFR gene (Grillari et al., 2001, J. Biotechnol. 87, 59-65). Thereby the expression level of the DHFR gene is lowered. This leads to increased sensitivity for MTX and more stringent selection conditions. Accordingly, a vector nucleic acid is provided, wherein the expression cassette (MASM) comprises an intron which is located 3' of the amplifiable selectable marker gene. A suitable intron may be obtained from the pSV2-DHFR vector (see e.g. above).

Said vector may comprise at least one additional expression cassette (PSM) comprising a prokaryotic selectable marker gene. Said expression cassette (PSM) is located between the expression cassettes (MSM) and (MASM). Said selectable marker may provide a resistance to antibiotics such as e.g. ampicillin, kanamycin, tetracycline and/or chloramphenicol. Said expression cassette (PSM) is preferably arranged in the same 5' to 3' orientation as the other expression cassettes (POI), (MSM) and (MASM).

The DHFR gene works as a marker and a gene amplification gene. Selection may occur by culturing the cells in the absence of the appropriate metabolites (hypoxanthine and thymidine) thereby preventing growth of non-transformed cells. With the DHFR system, expression of the polypeptides of interest can be increased by exposing the cells to antifolates such as for example methotrexate (MTX), a drug that blocks the activity of DHFR. After a certain time of expo-

sure to MTX the majority of cells die, but a small number of cells usually survive that overproduce DHFR. Upon MTX treatment, ramped upwards in concentration, the surviving cells may frequently contain up to several hundred to a few thousand copies of the integrated vector embedded in chromosomes that are frequently elongated. Most respectively amplified cells produce more recombinant protein than the unamplified cells.

Several suitable DHFR enzymes and accordingly genes are known in the prior art that can be used in conjunction with the present invention. The DHFR may be a wildtype DHFR or a functional variant or derivative thereof. The term a "variant" or "derivative" include DHFR enzymes having one or more amino acid sequence exchanges (e.g. deletions, substitutions or additions) with respect to the amino acid sequence of the respective DHFR enzyme, fusion proteins comprising a DHFR enzyme or functional fragment thereof and DHFR enzymes which have been modified to provide an additional structure and/or function, as well as functional fragments of the foregoing, which still have at least one function of a DHFR enzyme. The DHFR gene is preferably selected from the group consisting of wildtype DHFR, a DHFR variant having a reduced MTX sensitivity compared to wildtype DHFR and a DHFR variant having an enhanced MTX sensitivity compared to wildtype DHFR. According to one embodiment, the DHFR gene is the wild type DHFR gene. According to a different embodiment, the DHFR gene encodes a less functional variant of DHFR. This leads to an increased sensitivity for MTX and more stringent selection conditions. This can be achieved e.g. by placing an intron at the 3' end of the DHFR gene (see above). A different alternative could rely on the use of a DHFR mutant/variant having a higher sensitivity towards MTX than the wildtype DHFR. These embodiments are particularly beneficial in case the vector is used in host cells which are DHFR.

In case one desires to use the DHFR system in host cells incorporating a copy of the DHFR gene in their own genome (e.g. CHO DHFR⁺), it is preferred that a mutant/variant of the DHFR gene is used, which is less sensitive towards antifolates such as MTX than the wildtype DHFR and is thus to a certain extent antifolate respectively MTX-resistant. E.g. due to mutations in the gene the sensitivity of the DHFR gene towards MTX can be significantly reduced so that said variant can be used at higher antifolate (MTX) concentrations. Said less antifolate and in particular MTX sensitive DHFR variant can e.g. possess a reduced antifolate/MTX binding affinity. Respective DHFR variants can be used to "overtitrate" endogeneous DHFR expression in wild type cell lines. Respective "resistant" or less sensitive DHFR variants are well known in the prior art.

The expression vector can be selected from the group consisting of

- (a) a circular or linear vector nucleic acid comprising the following genetic elements in the indicated arrangement, wherein the 5' to 3' direction is indicated by the →:
 - I. Promoter of the (MASM) expression cassette (→)
 - II. Gene encoding the mammalian amplifiable selectable marker of the (MASM) expression cassette (→)
 - III. Optionally an intron of the (MASM) expression cassette (→)
 - IV. PolyA site of the (MASM) expression cassette (→)
 - V. Promoter of the (POI) expression cassette (→)
 - VI. Intron of the (POI) expression cassette (→)
 - VII. Polynucleotide encoding a polypeptide of interest, which is inserted in the (POI) expression cassette (→)

11

VIII. PolyA site of the (POI) expression cassette (→)

IX. Promoter of the (POI) expression cassette (→)

X. Intron of the (POI) expression cassette (→)

XI. Polynucleotide encoding an additional polypeptide of interest, which is inserted in the (POI) expression cassette (→)

XII. PolyA site of the (POI) expression cassette (→)

XIII. Promoter of the (MSM) expression cassette (→)

XIV. Gene encoding the mammalian selectable marker of the (MSM) expression cassette (→)

XV. PolyA site of the (MSM) expression cassette (→)

XVI. PSM expression cassette (→) or (←)

XVII. Linearization restriction site if the vector nucleic acid is circular;

(b) a vector nucleic acid as shown as Seq. ID No. 1 or Seq. ID No. 16 or a derivative thereof, comprising the same configuration respectively arrangement of genetic elements.

A preferred embodiment of variant (a) in its circular form is shown in FIG. 1 and corresponding Table. 1.

The vector according to the present invention can be obtained by arranging the expression cassettes in the proper order and orientation as is described in detail above. Arrangement of the expression cassettes/genetic elements can be done by using suitable restriction enzymes and cloning strategies in order to assemble the expression vector.

Accordingly, also a method for producing a vector nucleic acid as described above is provided, wherein said method comprises arranging at least the following genetic elements (a) at least one expression cassette (POI) for expressing a polypeptide of interest;

(b) an expression cassette (MSM) comprising a mammalian selectable marker gene;

(c) an expression cassette (MASM) comprising a mammalian amplifiable, selectable marker gene;

such that the expression cassette (POI) is flanked 5' by the expression cassette (MASM), the expression cassette (MSM) is located 3' from the expression cassette (POI) and wherein the expression cassettes (MASM), (POI) and (MSM) are arranged in the same 5' to 3' orientation.

In case a circular vector nucleic acid is produced, the genetic elements are assembled such that the expression cassette (MSM) is accordingly located 3' of the expression cassette (POI) and the expression cassette (MASM) is located 3' of the expression cassette (MSM).

The vector according to the present invention can be used for expressing the polypeptide of interest in many different mammalian host cells. The expression vector of the present invention is usually integrated into and maintained in the genome. There are two main formats of host cells, cultures of adherent cells and suspension cultures. Suspension cultures are preferred. Most established cell lines maintain their anchorage-dependent character unless special efforts are undertaken to adapt them to the suspension growth. Commercially available media formulations facilitate the transition. Basically any mammalian host cells can be used in conjunction with the present invention as long as they allow the expression of a polypeptide. Suitable mammalian host cells for the purposes of the present invention include but are not limited to cells derived from mice (e.g. COP, L, C127, Sp2/0, NS-0, NS-1, At20 or NIH3T3), rats (PC12, PC12h, GH3, MtT), hamsters (e.g. BHK, CHO and DHFR gene defective CHO), monkeys (e.g. COS1, COS3, COS7, CV1 and Vero) and humans (e.g. HeLa, HEK-293, retina-derived PER-C6, cells derived from diploid fibroblasts, myeloma cells and HepG2). Preferably, the host cell is a CHO cell. The vector construction according to the present invention is

12

particularly suitable for producing polypeptides in rodent cells such as CHO and DHFR gene defective CHO cells.

Also provided are mammalian host cells, comprising the expression vector according to the present invention. Also provided is a stable cell line, comprising an expression vector according to the present invention or a segment thereof in the genome. The segment shall comprise at least the expression cassettes decisive for the present invention. As the vector and its characteristics as well as suitable host cells are described in detail above, we refer to the above disclosure. Accordingly, also a method for producing a host cell as described above is provided, wherein the host cell is transfected with the vector nucleic acid according to at least one of the claims 1 to 16.

There are several appropriate methods known in the prior art for introducing an expression vector into a mammalian host cell. Respective methods include but are not limited to calcium phosphate transfection, electroporation, lipofection, biolistic- and polymer-mediated genes transfer. Suitable host cells are described above.

After introduction of the expression vector nucleic acid into the host cell(s), the obtained transformants are cultured under selective conditions suitable for assaying the expression of the mammalian selectable marker gene enclosed in the expression cassette (MSM). This means, that for example when the mammalian selectable marker gene is an antibiotic resistance gene, transformants are cultured in a medium containing the corresponding antibiotic active in mammalian cells and the transformants which are viable under such conditions are selected, thus enabling the obtainment of transformants which express the marker gene and thus incorporated the vector. Additionally, a second selection step may be performed by culturing the transformants in a selection medium adapted for selecting the amplifiable, selectable marker gene comprised in the expression cassette (MASM). E.g. in case DHFR is used as an amplifiable, selectable marker gene, the transformants can be cultured in a nucleotide or purine-free medium in the presence of a DHFR inhibitor.

In case an inducible promoter is used in at least one expression cassette, a corresponding induction signal should be provided in order to commence expression of the polypeptide.

In order to make use of the DHFR selection/amplification system, said host cells may be cultured in the presence of a DHFR inhibitor. Suitable DHFR inhibitors are antifolates such as e.g. MTX. The concentration of antifolate/MTX used depends on the host cell and the DHFR variant incorporated in the vector. The concentration range can be chosen for multistep amplification procedures in DHFR⁻ host cells for example at values around 5 nM-20 nM ranging to values of 500 nM to 1000 nM or even higher for secondary or further amplification steps. For DHFR⁺ cells starting concentrations are usually higher in the range of 100 nM to 750 nM, preferably 500 nM in the first steps and 500 nM to 1000 nM and above for further amplification steps. Suitable DHFR variants are described above.

In order to make use of the GS selection/amplification system said host cells may be cultured in the presence of e.g. MSX. The concentration of MSX used depends on the host cell. The concentration range can be chosen between from about 15 to 150 μM, 20 to 100 μM and 25 to 50 μM. These ranges are particularly suitable for NSO and CHO cells.

With the expression vector according to the present invention, several different polypeptides of interest may be expressed/produced. The term polypeptide refers to a mol-

ecule comprising a polymer of amino acids linked together by a peptide bond(s). Polypeptides include polypeptides of any length, including proteins (e.g. having more than 50 amino acids) and peptides (e.g. 2-49 amino acids). Polypeptides include proteins and/or peptides of any activity or bioactivity, including e.g. bioactive polypeptides such as enzymatic proteins or peptides (e.g. proteases, kinases, phosphatases), receptor proteins or peptides, transporter proteins or peptides, bactericidal and/or endotoxin-binding proteins, structural proteins or peptides, immune polypeptides, toxins, antibiotics, hormones, growth factors, vaccines or the like. Said polypeptide may be selected from the group consisting of peptide hormones, interleukins, tissue plasminogen activators, cytokines, immunoglobulins, in particular antibodies or antibody fragments or variants thereof. Said immunoglobulin can be of any isotype. Very often IgG (e.g. IgG1) molecules are produced/needed as therapeutic proteins. An antibody fragment is any fragment of an antibody comprising at least 20 amino acids from said whole antibody, preferably at least 100 amino acids, which at least still has an antigen binding capacity. The antibody fragment may comprise the binding region of the antibody such as a Fab fragment, a F(ab)₂ fragment, multibodies comprising multiple binding domains such as diabodies, triabodies or tetrabodies, single domain antibodies or affibodies. An antibody variant is a derivative of an antibody or antibody fragment having the same binding function but e.g. an altered amino acid sequence. Said antibody and/or antibody fragment may comprise a murine light chain, human light chain, humanized light chain, human heavy chain and/or murine heavy chain as well as active fragments or derivatives thereof. Hence, it can be e.g. murine, humane, chimeric or humanized.

The present invention also provides methods of producing a polypeptide of interest, said method comprising culturing at least one host cell comprising a vector nucleic acid according to the present invention in a cell culture medium under conditions allowing the expression of said polypeptide of interest.

In a next step, said polypeptide can be isolated/harvested from the cell culture. The expressed polypeptide of interest may be obtained by disrupting the host cells. The polypeptides may also be expressed, e.g. secreted into the culture medium and can be obtained therefrom. Also combinations of the respective methods are possible. Thereby, products, in particular polypeptides can be produced and obtained/isolated efficiently with high yield. The obtained polypeptide may also be subject to further processing steps such as e.g. purification and/or modification steps in order to produce the product of interest in the desired quality.

According to one alternative, said polypeptide of interest is secreted into the cell culture medium and subsequently isolated from the cell culture medium. The polypeptide is preferably an immunoglobulin molecule such as an antibody or a functional fragment thereof. In order to promote secretion of the polypeptide of interest a leader sequence can be used. Preferably, the leader sequence of an immunoglobulin molecule is used.

The expression vector according to the present invention as well as suitable host cells and polypeptides of interest are described in detail above; we refer to the above disclosure.

The method for producing the polypeptide of interest may comprise at least one of the following steps:

- isolating the polypeptide of interest from said cell culture medium and/or from said host cell; and/or
- processing the isolated polypeptide of interest.

The polypeptide of interest produced in accordance with the invention may be recovered, further purified, isolated and/or modified by methods known in the art. For example, the product may be recovered from the nutrient medium by conventional procedures including, but not limited to, centrifugation, filtration, ultra-filtration, extraction or precipitation. Purification may be performed by a variety of procedures known in the art including, but not limited to, chromatography (e.g. ion exchange, affinity, hydrophobic, chromatofocusing, and size exclusion), electrophoretic procedures (e.g., preparative isoelectric focusing), differential solubility (e.g. ammonium sulfate precipitation) or extraction.

According to one embodiment which is in particular advantageous for the production of pharmaceutical proteins/peptides, the host cell is cultured in suspension under serum-free conditions. The obtained polypeptide can afterwards be purified, e.g. by purifying the polypeptide present in the cell culture supernatant by using chromatographic methods (e.g. affinity purification).

Polypeptides produced according to the method of the present invention depict good stability properties. The results also show that the polypeptides are expressed in a functional form and hence in the right conformation. Accordingly, the invention also provides polypeptides obtained by the production method according to the present invention using the expression vector described in detail above. As is outlined above, polypeptides are obtained with a good yield. The polypeptide is preferably an immunoglobulin molecule such as an antibody or a functional fragment thereof.

FIG. 1 shows a circular vector nucleic acid according to a preferred embodiment of the present invention.

FIG. 2 shows the linearized version of the vector nucleic acid according to FIG. 1 in order to demonstrate the influence of the position of the linearization restriction site.

The numbers 1 to 17 shown in FIGS. 1 and 2 indicate the genetic elements/characteristics of the vector nucleic acid and are described in detail in the subsequent table 1. If not otherwise defined, the white arrows characterize promoters or promoter/enhancer elements; the striped boxes characterize intron elements, the black arrows symbolize the polynucleotides for expressing the polypeptide of interest; the checkered boxes characterize the polyA site; the checkered arrows the mammalian marker genes of the expression cassette (MSM) and (MASM); the striped arrow the prokaryotic selectable marker gene. As can be seen, all genetic elements are arranged in the same 5' to 3' orientation (indicated by the direction of the arrow). The vector nucleic acids pBW147, pBW154 and pBW160, which are described in further detail below, are respectively constructed.

TABLE 1

orientation and arrangement of the genetic elements according to a vector nucleic acid as shown in FIG. 1 and 2	
Numbering in FIG. 1 and 2	Genetic element
1	Promoter of the (POI) expression cassette (diagrammed by the white arrow). It is e.g. a CMV promoter/enhancer.
2	Intron of the (POI) expression cassette (diagrammed by the striped box). It is e.g. a RK-intron, as described above.
3	Polynucleotide encoding a polypeptide of interest, which is inserted in the (POI) expression cassette (diagrammed by the black arrow). According to the shown embodiment, it is the light chain of a monoclonal antibody (mAB-LC).
4	PolyA site of the (POI) expression cassette (diagrammed by the checkered box). It is e.g. a SV40 PolyA site.
5	Promoter of the (POI') expression cassette (diagrammed by the white arrow). It is e.g. a CMV promoter/enhancer.
6	Intron of the (POI') expression cassette (diagrammed by the striped box). It is e.g. a RK-intron, as described above.
7	Polynucleotide encoding an additional polypeptide of interest, which is inserted in the (POI') expression cassette (diagrammed by the black arrow). According to the shown embodiment, it is the heavy chain of a monoclonal antibody (mAB-HC).
8	PolyA site of the (POI') expression cassette (diagrammed by the checkered box). It is e.g. a SV40 PolyA site.
9	Promoter of the (MSM) expression cassette (diagrammed by the white arrow). It is e.g. a SV40 promoter/enhancer.
10	Gene encoding the mammalian selectable marker of the (MSM) expression cassette (diagrammed by the checkered arrow). It is e.g. the neo gene.
11	PolyA site of the (MSM) expression cassette (diagrammed by the bar). It is e.g. a synthetic PolyA site as described above.
12	PSM expression cassette (diagrammed by the striped arrow). It can e.g. comprise a prokaryotic selectable marker gene providing a resistance against ampicillin.
13	Linearization restriction site (diagrammed by the bar). Said site is preferably a unique restriction site.
14	Promoter of the (MASM) expression cassette (diagrammed by the white arrow). It is e.g. a SV40 promoter.
15	Gene encoding the mammalian amplifiable selectable marker of the (MASM) expression cassette (diagrammed by the checkered arrow). It is e.g. the DHFR gene.
16	Intron in the (MASM) expression cassette (diagrammed by the bar). This intron is optionally present.
17	PolyA site of the (MASM) expression cassette (diagrammed by the checkered box). It is e.g. a SV40 PolyA site.

Subsequently, suitable examples for the described vector elements are given, which are, however, non-limiting.

As mammalian amplifiable selectable marker the use of DHFR is preferred. A suitable example of a wildtype mouse DHFR polynucleotide is provided with Seq. ID No. 5 which is preferably used in conjunction with the DHFR⁻ host cells. A suitable mutant form of DHFR is provided with Seq. ID No. 6. A respective mutant form is preferably used together with the DHFR⁺ cells. Seq. ID No. 12 shows a mutant DHFR including an intron suitable for further increasing the selection pressure (see above). Also functional variants or fragments of the foregoing can be used.

As mammalian selectable marker gene the use of neo is preferred. A suitable sequence is provided with Seq. ID No. 7. Also functional variants or fragments thereof can be used.

As a promoter sequence for driving the expression of the polypeptide of interest the use of a CMV promoter is preferred. A suitable sequence is provided with Seq. ID No. 8. Also functional variants or fragments thereof can be used.

As a promoter sequence for driving the expression of the selectable marker genes MSM and MASM the use of SV40 promoter is preferred. A suitable sequence is provided with Seq. ID No. 9. Also functional variants or fragments thereof can be used.

As a polyadenylation sequence for the polypeptides of interest and/or the MASM a SV40 poly A site can be used. A suitable sequence is shown as Seq. ID No. 10. Also functional variants or fragments thereof or a reversed orientation (late or early SV40 poly A site) can be used.

As intron sequence for the expression cassette (POI) encoding the polypeptide of interest an Rk intron may be used. A suitable sequence is provided with Seq. ID No. 11. Also functional variants or fragments thereof can be used.

As synthetic polyadenylation site which can be used e.g. in conjunction with the mammalian selectable marker (MSM) is shown as Seq. ID No. 13. Also functional variants or fragments thereof can be used.

A suitable bacterial selectable marker (PSM) is e.g. the beta-lactamase gene which provides ampicillin resistance. A suitable sequence is provided with Seq. ID No. 14. Also functional variants or fragments thereof can be used.

Furthermore, the vector nucleic acid may comprise at least one multiple cloning site (MCS) for inserting e.g. a polynucleotide encoding a polypeptide of interest. MCS can be provided 3' and 5' of the polynucleotide encoding the polypeptide of interest. Suitable MCS sites are provided as Seq. ID No. 4 (preferably located at the 5' site/region) and

17

Seq. ID No. 15 (preferably located at the 3' site/region). These MCS sites can be used e.g. in order to introduce the polynucleotide encoding the polypeptide of interest.

Particularly preferred vector nucleic acids are shown as Seq. ID No. 1 (comprising the wildtype DHFR gene, said vector is particularly useful for the DHFR⁻ system) and Seq. ID No. 16 (comprising a mutated DHFR gene, said vector is particularly useful for the DHFR⁺ system).

All references cited herein are incorporated by reference and thus form part of the present disclosure.

EXAMPLES

The present invention is now described by means of non-limiting examples, which however, constitute preferred embodiments of the present invention.

I. Cell Culture Methods and Transfection

Subsequently, appropriate methods for transfecting and culturing the host cells according to the present invention for expressing a polypeptide of interest are described by means of examples.

Example 1

Cell Culturing

CHO cells are cultivated in a suitable CHO medium such as e.g. ExCell81134 (obtained from SAFC Biosciences). Cells are passaged 2-3 times per week into fresh media and are maintained in logarithmic growth phase throughout the study.

Example 2

Transfection Strategy

For transfection, parental CHO cells in exponential growth phase with a viability over 90% are used. Transfections by lipofection are done using the DMRIE-C reactant according to the instructions of the manufacturer (Invitrogen). The cell amount is adjusted to 1×10^6 cells in OptiMEM I medium (Invitrogen). For lipofection, 2 μ g or 4 μ g of the expression vector and 4 μ l of the DMRIE-C reagent are mixed together for 28 min at room temperature and added to the cells for 4 h at 37° C. Cells are then diluted to 2×10^5 cells/ml culture medium and incubated for 2 days at 37° C. and 5% CO₂.

Example 3

Neomycin Selection and Gene Amplification

The neomycin selection marker located on the expression vector nucleic acid allows selection for G418 resistance. For selection of transfectants, cells are cultivated in the presence of 0.8 mg/ml G418 (Invitrogen) for approximately two weeks. Two weeks after transfection and G418 selection, pool populations consisting predominantly of G418 resistant cells emerge. Cells are then cultivated in the absence of nucleotides for about two weeks. Gene amplification is then initiated by the addition of 20 nM MTX to the culture

18

medium. After three weeks of cultivation, an amplified heterogeneous cell pool is generated. The DHFR (dihydrofolate reductase) selection/amplification marker allows amplification of the DHFR gene as well as of the transgene by adding the folic acid analogue methotrexate (MTX) to the culture media, resulting in increased titers for transfection pools. After crisis recovery, pools then undergo a second and a third amplification step using higher MTX concentration each for approximately two weeks (100 nM and 500 nM MTX). At each step cells are frozen after pool recovery.

Example 4

Establishment of Clonal Cell Lines

To obtain a clonal cell line (i.e., a cell line derived from a single cell), the pool of stably transfected cells can be diluted and seeded out in 96 well plates with a cell density of 0.3-0.5 cells per well (limited dilution). Cells forming a distinct colony are scaled up using standard procedures. Eventually, individual clones are evaluated for recombinant polypeptide expression, with the highest producers being retained after cultivation and analysis. From these candidates, the cell line with appropriate growth and productivity characteristics is chosen for production of the recombinant protein. The productivity can usually be further improved by establishing/adapting the culturing conditions i.e. by adding additives such as peptones.

II. Vector Constructions

Several vector assemblies according to the teachings of the present invention are feasible. As the individual elements of the vector are known in the prior art, suitable vectors can be assembled e.g. by sequencing or amplification and appropriate cloning of the basic genetic elements and expression cassettes in the desired orientation. Respective cloning methods are state of the art and also the sequence of the genetic elements described above are described in the prior art. Subsequently, the generation of several vector constructs are described by way of example. However, it is understood by those of skill in the art that several other embodiments and ways to obtain respective vectors are suitable and readily available.

In order to facilitate understanding of the arrangement of the vector constructs described herein by way of example and their precursor vectors, tables 1 and 2 provide an overview over the main genetic elements comprised in these vectors, their order and orientation. Of course, only the main elements are shown, the vectors may, however, comprise additional genetic elements or backbone sequences. Each column in the table represents one vector construct. From the top row to the bottom row the genetic elements of the expression cassettes are listed in the order of their arrangement and their orientation on the vector. As the described vectors are circular, the element shown in the last row of each column is in fact adjacent to the genetic element shown in the first row (of course, backbone sequences may be present). The orientation of each genetic element is indicated by the arrows. The arrowhead points to the 3' direction of the respective genetic element.

TABLE 2

order of the genetic elements in the precursor vectors			
pBW133 10416 bp	pBW139 9213 bp	pBW146 9247 bp	pBW159 11122 bp
CMVprom/enh →	CMVprom/enh →	CMVprom/enh, comprising a SpeI (153) restriction site →	CMVprom/enh →
RK-intron →	RK-intron →	RK-intron →	RK-intron →
mAB-LC →	mAB-LC →	mAB-LC →	mAB-LC →
MCS I	MCS	MCS	MCS
SV40polyA →	SV40polyA →	SV40polyA →	SV40polyA →
DraIII restriction site (2365)	CMV prom/enhan →	CMV prom/enhan comprising a SpeI restriction site (2519) →	CMV prom/enhan →
DHFR* carying a ScaI restriction site (2870); reverse orientation ←	RK-intron →	RK-intron →	RK-intron →
SV40prom/enhan; reverse orientation ←	MCS	MCS2	mAB-HC →
DraIII restriction site (3651)	mAB-HC →	mAB-HC →	MCS
SV40prom/enhan →	MCS	MCS	T3 promoter
Neo →	SV40polyA →	T3 promoter	SV40polyA →
CMV prom/enhan →	Phage fl region comprising a DraIII restriction site (5456) →	SV40polyA →	Phage fl region →
RK-intron →	SV40prom/enhan →	Phage fl region →	SV40prom/enhan →
MCS2	Neo →	SV40prom/enhan comprising a SV40 minimum origin of replication →	Neo →
mAB-HC →	SV40polyA →	Neo →	Synth Poly A
SV40polyA →	Amp comprising a ScaI restriction site (7828) →	Synth polyA	Amp →
Amp carrying ScaI (9031) →	BglII restriction site (9209), 5' to the CMV prom/enh	Amp →	3 pA sites
		BglII restriction site (9243), 5' adjacent of the CMVprom/enh	intron
			DHFR; reverse orientation ← SV40prom; reverse orientation ← ScaI restriction site (11113)

50

TABLE 3

order of the genetic elements in the expression vectors		
pBW147 11053 bp	pBW154 11109 bp	pBW160 11122 bp
CMVprom/enh, comprising a SpeI restriction site (153) →	CMVprom/enh →	CMVprom/enh →
RK-intron →	RK-intron →	RK-intron →
mAB-LC →	mAB-LC →	mAB-LC →
SV40polyA →	SV40polyA →	SV40polyA →
CMV prom/enhan comprising a SpeI restriction site (2519) →	CMV prom/enhan →	CMV prom/enhan →
RK-intron →	RK-intron →	RK-intron →
mAB-HC →	mAB-HC →	mAB-HC →
SV40polyA →	SV40polyA →	SV40polyA →

TABLE 3-continued

order of the genetic elements in the expression vectors		
pBW147 11053 bp	pBW154 11109 bp	pBW160 11122 bp
SV40prom/enhan →	SV40prom/enhan →	SV40prom/enhan →
Neo →	Neo →	Neo →
Synth polyA	Synth polyA	Synth polyA
Amp →	Amp →	Amp →
55		
Swa I restriction site (9288)	SwaI restriction site (9243)	SwaI restriction site (9256)
SV40prom/enhan →	SV40 prom →	SV40 prom →
DHFR* →	DHFR →	DHFR →
Bgh pA site →	Intron	Intron
	SV40polyA	SV40polyA
65		

The abbreviations in the above tables 1 to 3 and in FIGS. 1 and 2 have the regular meanings as apparent for the person

of skill in the art and as described above, and have in particular the following meanings:

MCS=multiple cloning site
 mAB-HC=monoclonal antibody heavy chain
 mAB-LC=monoclonal antibody light chain
 intron=see Grillari et al, 2001, 3. Biotechnol. 87, 59-65
 prom/enh=promoter/enhancer

Example 5

Construction of Expression Vector pBW147

In this setup the tandem configuration of mAB genes and the DHFR* (mutant variant having a lower sensitivity to MTX than the wild type DHFR) combined with the bgh pA-site, is tested. The DHFR* cassette is placed 5' before the expression cassette (POI), comprising the mAB-LC, so that all open reading frames are placed in one reading direction. The assembly of pBW147 is shown in table 3.

pBW147 can be constructed from pBW133 (please also refer to table 2). The construction of pBW147 is described herein.

Construction of pBW133

The vector constructions described below are based on the commercially available pCl-neo expression vector (Promega Cooperation, USA). The complete DNA sequence is publicly available (GenBank/EMBL Accession number: U47120). A new multiple cloning site is introduced in pClneo.

The two strands of the multiple cloning site are synthesized de novo. pClneo is cut with NheI and XmaI. The old MCS is removed by gel electrophoresis. The new multiple cloning site is synthesized in the way that the terminal 4 nucleotides of the 5' end of the antisense strand and the 3' terminal end of upper DNA strand are not synthesized. After annealing of both strands compatible ends for NheI and XmaI are created.

The sequence of the new multiple cloning site is as follows (see Seq. ID No. 2):

ApaISgrAI				
AgeI	PmeI	EcoRV	PshAI	
EcoO109I	BstEII	PmlI	BspEI	AscI

The resulting plasmid of the ligation of pClneo with the new MCS is deemed pCl-neo-2 for description purposes. pCl-neo-2 is further modified by introducing the pRK intron from pRK5 (BD PharMingen). Therefore, pCl-neo-2 is digested with ApaI. Blunt ends are created by T4 polymerase treatment. Then the plasmid is digested with NdeI. pRK5 is digested with NdeI and NruI (blunt end cutter). The RK intron containing fragment is isolated and ligated with the pClneo2 backbone. The resulting plasmid is pClneo2RK.

To bring both expression cassettes on one vector, the vector pClneoDHFR*-RK can be obtained. pClneoDHFR*-RK is obtained as follows:

The DHFR* expression cassette is amplified by PCR from vector pCHI-LC (Simulect SP2/0 light chain expression vector). The primers are BB35 (GGGCAC-TACGTGCCGCGGATTAAATGCGGCCG-CATATGGTGC ACT—Seq. ID No. 3) and BB36 (GGGCACGTAGTGT TTTATTAGGG-GAGCAGAGAACTTGAA—Seq. ID No. 4).

The PCR fragment is cloned into pClneoRK via DraIII restriction digestion giving vector pClneoDHFR*-RK. pClneoDHFR*-RK is opened by digestion with Eco01091. In

order to create blunt ends, treatment with the Klenow enzyme is performed afterwards.

The expression cassette from pClneo2RK is excised by digesting the plasmid with BglII, NgoMIV and StuI. After ligation of the two fragments the “empty” expression vector pCHO2neoN is created. Into pCHO2neoN the antibody light chain gene is inserted via the MluI and Sall restriction site thereby creating a vector construct, to which we refer as pBW108. The antibody gene is therefore amplified using primers which contain the two restriction sites.

The mAB heavy chain is inserted into pBW108 via PmeI and AscI digestion of the vector, thereby obtaining a vector construct deemed pBW111 for description purposes. The heavy chain is PCR amplified with the 5' end generating blunt ends and the 3' end of the gene containing the AscI restriction site.

In pBW111 the 5' non-translated region end of the light chain is exchanged because an additional ATG codon is present in front of the light chain cDNA. This is accomplished by excising a BglII/MluI fragment from pBW111 and replacing it with the corrected fragment. The new plasmid is deemed pBW133. pBW133 is the first vector with all genes on one plasmid. The arrangement of the genes is: LC-DHFR (opposite direction)-neo-HC (see also table 2). This vector is one of the starting materials that can be used for obtaining vectors according to the teachings of the present invention. However, it is clear that there are several other ways to obtain respective vectors.

Construction of pBW139

The second vector construct that can be used for obtaining pBW147 has the configuration of pBW139. pBW139 can be created from pBW115. For the construction of pBW115, the heavy chain gene is cloned into pClneoRK (see above). Therefore, pClneoRK is digested with MluI and NruI (blunt end cutter), whereas the heavy chain PCR fragment is digested with AscI (3') (compatible to MluI) and is blunt 5'. The resulting plasmid is deemed pBW115.

pBW115 is digested with ScaI and BglII. Then a Klenow fill-in is done to create blunt ends. The light chain expression cassette is excised from pBW133 with ScaI and DraIII. In order to create blunt ends, T4-DNA polymerase treatment is done. Resulting from the ligation is a vector having a configuration as pBW139 (see table 2).

Assembly of pBW147

For obtaining pBW147, pBW133 is digested with SpeI, XhoI. The fragment containing parts of the CMV promoter and the first part of the heavy chain is isolated and ligated to pBW139, which is also cut with SpeI, XhoI. In the resulting vector the heavy-chain cassette is found without a disturbing additional ATG codon. In order to bring back the light chain into the vector, pBW139 is digested with SpeI. The LC containing fragment is inserted into pBW148 which is opened with SpeI. The resulting plasmid has a configuration as pBW146 (see table 2).

In pBW146 the DHFR gene from pBW112 (expression vector from another project) is inserted. However, the DHFR gene could also be obtained from a different source, depending on the kind of DHFR variant desired. pBW146 is digested with BglII. Afterwards the DHFR cassette is PCR amplified with primers containing BglII and BamHI restriction sites. The PCR fragment is digested with the two enzymes and inserted in the fitting BglII site of pBW146. The resulting plasmid has a configuration as pBW147, wherein all expression cassettes have the same orientation. The structure is shown in table 3.

This expression vector can be used to obtain stable transfections. In order to further increase the expression

yield, a very MTX "sensitive" wild type DHFR variant can be chosen, wherein also the MTX concentrations should be adapted adequately.

Example 6

Construction of Expression Vector pBW154

For this vector, the tandem configuration of the mAB genes and the DHFR gene cassette from pSV2DHFR (wild type version of DHFR with high sensitivity to MTX) are tested. The DHFR expression cassette from pSV2DHFR (ATCC#374146) is amplified by PCR. The fragment contained the promoter and the polyA sites. As before, the oligos had BglII/BamHI restriction sites. The DHFR expression cassette is inserted in the BglII restriction site of pBW146, resulting in a vector construct having the same structure as pBW154. The structure of pBW154 is shown in table 3 and can be derived from FIGS. 1 and 2 which show a general example of a vector construct having a respective overall structure/configuration of the genetic elements. The sequence of pBW154 is provided as Seq. ID No. 1. The light chain polynucleotide is marked n (in the priority application indicated with the placeholder V), the heavy chain polynucleotide is marked n (in the priority application indicated with the placeholder Y) in Seq. ID No. 1. The features of pBW154 are summarized in Table 4. Of course, also other vector elements, e.g. different promoters, different enhancers, different Poly A sites and other elements such as different oris can be used. Furthermore, it is possible to switch the expression cassettes for the light and the heavy chain of the immunoglobulin molecule. However, the shown selection and arrangement of the vector elements is preferred. As is outlined above, also functional fragments of immunoglobulin molecules can be used. Therefore, the indicated "nnn" only serve the purpose of illustration and do not indicate any size restriction as smaller or larger immunoglobulin sequences can be present at the corresponding position. In order to alleviate comparison with FIGS. 1 and 2, which show the general construction of vectors according to the preferred embodiment of the invention, we have indicated the numbering of the corresponding elements in FIGS. 1 and 2.

TABLE 4

Base pair Start	End	Feature	Corresponding numbering in FIG. 1 and 2
1	743	CMV prom/enh	1
857	1000	RK-intron	2
1054	1766	mAB LC	3
1815	2036	SV40polyA	4
2367	3109	CMV prom/enh	5
3223	3366	RK-intron	6
3452	4863	mAB HC	7
4931	5152	SV40polyA	8
5766	6184	SV40prom	9
6229	7024	Neomycin phosphotransferase	10
7087	7135	Synthetic poly A	11
7546	8406	Beta lactamase antibiotic resistance gene	12
9243		Unique Linearisation site	13
9422	9617	SV40prom	14
9640	10204	DHFR	15

TABLE 4-continued

Base pair Start	End	Feature	Corresponding numbering in FIG. 1 and 2
9776	10426	Intron (Donor-Acceptor)	16
10909	11098	SV40polyA	17

All genetic elements are arranged in the same 5' to 3' orientation. With this vector construct using a wildtype DHFR, gene amplification as described above works very efficiently. The titer in a standard batch experiment can be increased by 10-20-fold. Herein, a great increase in the antibody expression titer is observed upon MTX amplification. Starting from G418 treatment, over the treatment without nucleotides up to several different concentrations with MTX (20 and 100 nM MTX), the titer constantly and considerably increases. However, using much higher MTX concentrations (e.g. 500 nM MTX) usually brings no further advantages with CHO cells, even though respective high concentrations can be used. The antibody titers obtained for pools over the selection/amplification process ranged from 2 to more than 60 mg/L when using standard culturing procedures. The expression titers can be further increased upon establishing clonal cell lines from the pools and using customized media to enhance cell expression as the obtainable titer also depends on the used medium.

Example 7

Construction of Expression Vector pBW160

The experiments also demonstrate that the orientation of the DHFR gene in the vector is decisive. In pBW146 (see above) an EcoRI restriction site is present. In order to have EcoRI as a single cutter present in the final expression vector, the site can be removed by digesting pBW146 with EcoRI, Klenow-Fill in and relegation. This results in plasmid having the configuration as pBW158 (not shown). The DHFR cassette can be integrated in pBW158, as is described above. Since both orientations (orientation as is shown in pBW159 and pBW160, see table 2 and 3) are automatically generated, both can be tested for expression levels. Our results show superior performance of the configuration with all open reading frames orientated in one 5' to 3' reading direction.

Vectors having a configuration such as pBW159 vector (see table 2), wherein the DHFR orientation is in reverse order of the mAB genes usually show only very low expression titers, even after MTX amplification (usually less than 1 mg/L). Vectors having a design such as pBW160 (see table 3), wherein the DHFR orientation is in frame with the mAB genes, can provide higher antibody titers of more than 5 mg/L and even more than 10 or even more than 15 mg/L (obtainable from the pools). Again, by establishing a clonal cell line and by using a high performance medium the titer yield can be further increased when using the vector constructs according to the present invention.

These experiments can demonstrate the advantage of the "in frame configuration" of the selection markers and the mAB coding genes as are used according to the teachings of the present invention. This result supports the finding that the 5' to 3' orientation of the vector elements is an important factor for high expression vectors. Furthermore, the expression stability is very favourable with the expression vectors according to the present invention.

25

The vector configuration according to the present invention enables the straight forward generation of cell pools with high cell specific productivities. Key elements are the 5' to 3' orientation, the chosen DHFR variants and the placement of the DHFR selection marker on the vector as well as the arrangement of the antibody genes and the second selection marker (neo) on the plasmid. The vector can also be used for the production of non-antibody proteins or peptides. As described above, with slight adaptations of the DHFR cassette, this system is also usable for gene amplification in the DHFR positive CHO-K1PD cell line. For gene amplification in DHFR⁺ host cells a mutated version of the DHFR gene is used (see above). The complete DHFR expression cassette of a vector comprising a mutated version of the DHFR gene such as pBW117 can be PCR amplified with primers incorporating a BamHI site. This fragment is then cloned into the BglII site of pBW158 resulting in the vector pBW165. With vectors having a configuration such as pBW165 comprising a mutated DHFR gene (and follow ups with other antibodies), high yielding cell lines can be generated in the CHO-K1-PD host cell, which is a DHFR⁺ cell line. An example of a respective vector sequence is provided as Seq. ID No. 16. Of course also different vector elements than the ones shown can be used, e.g. different promoters, different enhancers, different Poly A sites and/or other elements such as e.g. different oris. Furthermore, it is possible to switch the expression cassettes for the light and the heavy chain of the immunoglobulin molecule. However, the shown selection and arrangement of the vector elements is preferred. As is outlined above, full-length immunoglobulin molecules as well as functional fragments of immunoglobulin molecules can be expressed from the vector. In Seq. ID No. 16 only the site is indicated as insertion site, where the respective immunoglobulin sequence can be located/inserted in the final expression vector. Any immunoglobulin sequences can be present at the corresponding position. Furthermore, as is outlined above, it is also possible to express different polypeptides of interests.

Example 8

Small Scale Production of Antibodies with Transfected CHO Cells

For test in suspension cultures, cells are seeded at 1×10^5 cells/ml in 50 ml ExCell81134 medium (SAFC Biosciences) in a 250 ml round bottomed filter cap culture flask. Cells are shaken at 65 rpm in a Kühner Shaker ISF-4-W/incubator at 37° C. in a 10% CO₂ environment for the duration of the study. Single feeds with proprietary solutions are given according to a fixed feeding scheme beginning on the 4th day of cell expansion. On the 13th day, 1 ml samples are harvested and titer is measured using standard HPLC and a protein A column.

Cell culture supernatant resulting from shake flask cultures of the best clones is purified by protein A affinity chromatography.

Example 9

Protein A Purification of the Expressed Antibody

For Protein A purification about 27 mL cell free culture supernatant containing approximately 32.4 mg antibody is loaded onto a 0.5x10 cm MabSelect affinity column. After loading, the column is sufficiently rinsed and washed. Then

26

the antibody is eluted at pH 3-4. The eluate is analysed with standard HPLC using a protein A column. About 30.5 mg antibody are obtained.

III. Examples for Cell Specific Productivities and Yields

Clones which are selected after clonal expansion are tested for their productivity.

Example 10

Expression of an IgG1 Antibody

An IgG1 antibody is expressed. Clones are grown in the commercially available medium ExCell81134 (SAFC Biosciences). Feed solutions and conventional additives such as peptone are added. High productivity rates can be obtained when using the vector according to the present invention:

Clone	QP (pg/cell/day)
1	114
2	91
3	103

Qp=cell specific productivity.

Example 11

Expression of an IgG1 Antibody and an IgG4 Antibody

An IgG1 antibody and an IgG4 antibody are expressed. Clones are grown in a proper culture medium. Feed solutions and conventional additives such as peptone are added. High productivity rates can be obtained when using the vector according to the present invention:

Clone	IgG1 antibody QP (pg/cell/day)	IgG4 antibody QP (pg/cell/day)
1	76	
2	96	
3		73

Qp=cell specific productivity.

Example 12

Large Scale Production of Polypeptides with Transfected CHO Cells

The production of polypeptides in large scale can be done for example in wave, glass or stainless steel bioreactors. For that purpose the cells are expanded, usually starting from a single frozen vial, for example a vial from a Master Cell Bank. The cells are thawed and expanded through several steps. Bioreactors of different scale are inoculated with appropriate amounts of cells. The cell density can be increased by adding feed solutions and additives to the bioreactor. Cells are kept at a high viability for a prolonged time. Product titers in the reactor ranging from a few hundred milligrams per liter up to several grams per litre are achieved in the large scale. Purification can be done by

standard chromatography methodology, which can include affinity, ion exchange, hydrophobic interaction or size exclusion chromatography steps. The size of the bioreactor can be up to several thousand litres volume in the final scale (see also e.g. F. Wurm, Nature Biotechnology Vol. 22, 11, 2004, 1393-1398).

Example 13

Cloning Strategy for Introducing New Antibody Genes in the Vectors

One strategy—among others—for inserting new polypeptides of interest is as follows (explained by way of example using a vector having a configuration such as pBW154):

Cloning of the Light Chain Gene

The light chain gene can be PCR amplified with primers introducing a MluI site 5' of the ATG codon and a Sall site 3' of the gene. The PCR product is introduced into pBW154 via these two restriction enzymes. This leads to an intermediate vector consisting of just the light chain.

Cloning of the Heavy Chain Gene

The heavy chain gene can be PCR amplified with primers introducing a blunt end for usage of the vector's NruI site 5' of the ATG codon and a XbaI 3' site of the gene. The PCR product is introduced into pBW154 via these two restriction enzymes. This leads to an intermediate vector with the old light chain and the new heavy chain.

Assembly of the Final Vector

The new mAB-HC containing fragment is excised from the HC vector via Sall digestion. It is then inserted into the LC-intermediate vector via Sall to result in the final new LC-HC vector.

SEQUENCE LISTING

```

<160> NUMBER OF SEQ ID NOS: 16

<210> SEQ ID NO 1
<211> LENGTH: 11109
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Vector sequence pBW154;
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1)..(743)
<223> OTHER INFORMATION: CMV prom/enh
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (825)..(1024)
<223> OTHER INFORMATION: RK-intron
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (857)..(1000)
<223> OTHER INFORMATION: RK-intron region which is spliced out upon
expression
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1054)..(1767)
<223> OTHER INFORMATION: mAB LC (originally indicated in Seq. Id. No: 1
with symbol "v")
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1054)..(1767)
<223> OTHER INFORMATION: n is a, c, g, or t.
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1815)..(2036)
<223> OTHER INFORMATION: SV40polyA
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2367)..(3109)
<223> OTHER INFORMATION: CMV prom/enh
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (3191)..(3390)
<223> OTHER INFORMATION: RK-intron
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (3223)..(3366)
<223> OTHER INFORMATION: RK-intron which is spliced out upon expression
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (3452)..(4864)
<223> OTHER INFORMATION: mAB HC (originally indicated in Seq. Id. No: 1
with symbol "y")
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (3452)..(4864)
<223> OTHER INFORMATION: n is a, c, g, or t.
<220> FEATURE:

```

-continued

```

<221> NAME/KEY: misc_feature
<222> LOCATION: (4931)..(5152)
<223> OTHER INFORMATION: SV40 poly A
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (5247)..(5702)
<223> OTHER INFORMATION: f1 region
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (5766)..(6184)
<223> OTHER INFORMATION: SV40 prom
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (6229)..(7023)
<223> OTHER INFORMATION: Neomycin phosphotransferase gene
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (7087)..(7135)
<223> OTHER INFORMATION: Synthetic polyA
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (7546)..(8406)
<223> OTHER INFORMATION: Beta lactamase antibiotic resistance gene
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (9243)..(9243)
<223> OTHER INFORMATION: Unique linearisation site
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (9276)..(9623)
<223> OTHER INFORMATION: SV40prom
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (9521)..(9568)
<223> OTHER INFORMATION: SV40 minimum origin of replication
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (9640)..(10203)
<223> OTHER INFORMATION: DHFR gene
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (9776)..(10426)
<223> OTHER INFORMATION: Intron (Donor - Acceptor)
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (10910)..(11097)
<223> OTHER INFORMATION: SV40polyA

<400> SEQUENCE: 1

tcaatattgg ccattagcca tattattcat tggttatata gcataaatca atattggcta      60
ttggccattg catacgttgt atctatatca taatatgtac atttatattg gctcatgtcc     120
aatatgaccg ccattgttggc attgattatt gactagttat taatagtaat caattacggg     180
gtcattagtt catagcccat atatggagtt ccgcgttaca taacttacgg taaatggccc     240
gcctggctga ccgcccacg acccccgccc attgacgtca ataatgacgt atgttcccat     300
agtaacgcca atagggactt tccattgacg tcaatgggtg gagtatttac ggtaaactgc     360
ccacttggca gtacatcaag tgtatcatat gccaaagtac cccctattg acgtcaatga     420
cggtaaatgg cccgcctggc attatgcccc gtacatgacc ttatgggact ttactacttg     480
gcagtacatc tacgtattag tcatcgctat taccatgggtg atgcggtttt ggcagtacat     540
caatgggcgt ggatagcggg ttgactcacg gggatttcca agtctccacc ccattgacgt     600
caatgggagt ttgttttggc accaaaatca acgggacttt ccaaatgtc gtaacaactc     660
cgccccattg acgcaaatgg gcggtaggcg tgtacgggtg gaggtctata taagcagagc     720
tcgttttagt aaccgtcaga tcgcctggag acgccaacca cgctgttttg acctccatag     780
aagacaccgg gaccgatcca gcctccgagg ccgggaacgg tgcattggaa cgcggtattcc     840
ccgtgccaag agtgacgtaa gtaccgccta tagagtctat aggcccacc ccttggcttc     900

```

-continued

gtagaacgc	ggctacaatt	aatacataac	cttatgtatc	atacacatac	gatttaggtg	960
acactataga	ataacatcca	ctttgccttt	ctctccacag	gtgtccactc	ccagggtccaa	1020
ctgcacctcg	gttctatcga	aaacgcgtcc	accnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	1080
nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	1140
nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	1200
nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	1260
nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	1320
nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	1380
nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	1440
nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	1500
nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	1560
nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	1620
nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	1680
nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	1740
nnnnnnnnnn	nnnnnnnnnn	nnnnnnngtc	gaccceggcg	gcegettccc	tttagtgagg	1800
gttaatgctt	cgagcagaca	tgataagata	cattgatgag	tttgacaaa	ccacaactag	1860
aatgcagtga	aaaaaatgct	ttatttgtga	aatttgtgat	gctattgctt	tatttghtaac	1920
cattataagc	tgcaataaac	aagttaacaa	caacaattgc	attcatttta	tgtttcaggt	1980
tcagggggag	atgtgggag	ttttttaaag	caagtaaac	ctctacaaat	gtggtaaaat	2040
ccgataagga	tcgatccggg	ctggcgtaat	agcgaagagg	cccgcaccga	tcgcccttcc	2100
caacagttgc	gcagcctgaa	tggcgaatgg	acgcgccctg	tagcggcgca	ttaagcgcgg	2160
cgggtgtggt	ggttacgcgc	agcgtgaccg	ctacacttgc	cagcgcctca	gcgcccgcctc	2220
cttctgcttt	cttcccttcc	tttctcgcca	cgctcgccgg	ctttccccgt	caagctctaa	2280
atcgggggct	ccctttaggg	ttccgattta	gagctttacg	gcacctegac	cgcaaaaaac	2340
ttgatttggg	tgatggttca	cgatcttcaa	tattggccat	tagccatatt	attcattggt	2400
tatatagcat	aatcaatat	tggtattgg	ccattgcata	cgttgtatct	atatcataat	2460
atgtacattt	atattggctc	atgtccaata	tgaccgccat	gttggcattg	attattgact	2520
agttattaat	agtaatcaat	tacgggggtca	ttagttcata	gcccatatat	ggagttccgc	2580
gttacataac	ttacggtaaa	tgccccgcct	ggctgaccgc	ccaacgaccc	ccgccattg	2640
acgtcaataa	tgacgtatgt	tcccatagta	acgccaatag	ggactttcca	ttgacgtcaa	2700
tgggtggagt	atctacggta	aactgcccac	ttggcagtac	atcaagtgtg	tcatatgccca	2760
agtacgcccc	ctattgacgt	caatgacggg	aatggccccg	cctggcatta	tgcccagtac	2820
atgaccttat	gggactttcc	tacttggcag	tacatctacg	tattagtcat	cgctattacc	2880
atgggtgatgc	ggttttggca	gtacatcaat	ggcgtggat	agcggtttga	ctcacgggga	2940
ttccaagtc	tccaccccat	tgacgtcaat	gggagtttgt	tttggacca	aatcaacgg	3000
gactttccaa	aatgtcgtaa	caactccgcc	ccattgacgc	aatggggcg	taggcgtgta	3060
cgggtggagg	tctatataag	cagagctcgt	ttagtgaacc	gtcagatcgc	ctggagacgc	3120
catccacgct	gttttgacct	ccatagaaga	caccgggacc	gatccagcct	ccgcgccgg	3180
gaacggtgca	ttggaacgcg	gattccccgt	gccaaagagt	acgtaagtac	cgctataga	3240

-continued

gtctataggc	ccaccccctt	ggcttcgcta	gaacgcggct	acaattaata	cataacctta	3300
tgtatcatac	acatacgatt	taggtgacac	tatagaataa	catccacttt	gcctttctct	3360
ccacaggtgt	ccactcccag	gtccaactgc	acctcggttc	tatcgcgatt	gaattccccg	3420
gggatcctct	agggtgaccg	tttgtgccac	cnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	3480
nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	3540
nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	3600
nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	3660
nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	3720
nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	3780
nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	3840
nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	3900
nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	3960
nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	4020
nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	4080
nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	4140
nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	4200
nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	4260
nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	4320
nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	4380
nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	4440
nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	4500
nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	4560
nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	4620
nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	4680
nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	4740
nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	4800
nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	4860
nnnngcgcg	tggtagctct	agagtcgacc	cggcgcgccg	cttcccttta	gtgagggtta	4920
atgcttcgag	cagacatgat	aagatacatt	gatgagtttg	gacaaaccac	aactagaatg	4980
cagtgaaaaa	aatgctttat	ttgtgaaatt	tgtgatgcta	ttgctttatt	tgtaaccatt	5040
ataagctgca	ataacaagt	taacaacaac	aattgcatte	attttatggt	tcaggttcag	5100
ggggagatgt	gggaggtttt	ttaaagcaag	taaaacctct	acaatgtgg	taaaatccga	5160
taaggatcga	tccgggctgg	cgtaatagcg	aagaggcccg	caccgatcgc	ccttcccaac	5220
agttgcgcag	cctgaatggc	gaatggacgc	gccctgtage	ggcgcatata	gcgcgcgggg	5280
tgtggtggtt	acgcgcagcg	tgaccgctac	acttgccagc	gccctagcgc	ccgctccttt	5340
cgctttcttc	ccttcctttc	tcgccacggt	cgccggcttt	ccccgtcaag	ctctaaatcg	5400
ggggctccct	ttagggttcc	gatttagagc	tttacggcac	ctcgaccgca	aaaaacttga	5460
tttgggtgat	ggttcacgta	gtgggccatc	gccctgatag	acggtttttc	gccctttgac	5520
gttggagtcc	acgttcttta	atagtggact	cttgttccaa	actggaacaa	cactcaaccc	5580
tatctcggtc	tattcttttg	atttataagg	gattttgccc	atttcggcct	attggttaaa	5640

-continued

aaatgagctg	atttaacaaa	tatttaacgc	gaattttaac	aaaatattaa	cgtttacaat	5700
ttcgctgat	gcggtatfff	ctccttacgc	atctgtgagg	tatttcacac	cgcatagcg	5760
gatctgcgca	gcaccatggc	ctgaaataac	ctctgaaaga	ggaacttgg	taggtacctt	5820
ctgaggcgga	aagaaccagc	tgtggaatgt	gtgtcagtta	gggtgtgga	agtccccagg	5880
ctccccagca	ggcagaagta	tgcaaagcat	gcatctcaat	tagtcagcaa	ccaggtgtgg	5940
aaagtcccca	ggctccccag	caggcagaag	tatgcaaagc	atgcatctca	attagtcagc	6000
aaccatagtc	ccgcccctaa	ctccgcccct	cccgcacct	actccgccc	gttccgccc	6060
ttctccgccc	catggctgac	taattttttt	tatttatgca	gaggccgagg	ccgctcggc	6120
ctctgagcta	ttccagaagt	agtgaggagg	cttttttga	ggcctaggct	tttgcaaaaa	6180
gcttgattct	tctgacacaa	cagtctcgaa	cttaaggcta	gagccaccat	gattgaacaa	6240
gatggattgc	acgcagggtc	tccggccgct	tgggtggaga	ggctattcgg	ctatgactgg	6300
gcacaacaga	caatcggtg	ctctgatgcc	gccgtgttcc	ggctgtcagc	gcaggggccc	6360
ccggttcttt	ttgtcaagac	cgacctgtcc	ggtgccctga	atgaactgca	ggacgaggca	6420
gcgcggtat	cgtggctggc	cacgacgggc	gttccttgcc	cagctgtgct	cgacgttgtc	6480
actgaagcgg	gaagggactg	gctgctattg	ggcgaagtgc	cggggcagga	tctcctgtca	6540
tctcaccttg	ctcctgccga	gaaagtatcc	atcatggctg	atgcaatgcg	gcggctgcat	6600
acgcttgatc	cggctacctg	cccattcgac	caccaagcga	aacatcgcat	cgagcgagca	6660
cgtactcgga	tggaagccgg	tcttgtcgat	caggatgatc	tggacgaaga	gcatcagggg	6720
ctcgcgccag	ccgaactggt	cgccaggctc	aaggcgcgca	tgcccagcgg	cgaggatctc	6780
gtcgtgacct	atggcgatgc	ctgcttgccg	aatatcatgg	tggaaaatgg	ccgcttttct	6840
ggattcatcg	actgtggccg	gctgggtgtg	gcgaccgct	atcaggacat	agcgttggct	6900
acccgtgata	ttgctgaaga	gcttggcggc	gaatgggctg	accgcttctc	cgtgctttac	6960
ggtatcgccg	ctcccgattc	gcagcgcac	gccttctatc	gccttcttga	cgagttcttc	7020
tgagcgggac	tctgggggtc	gaaatgaccg	accaagcgc	gcccacactg	ccatcacgat	7080
ggccgcaata	aaatatcttt	atcttcatta	catctgtgtg	ttggtttttt	gtgtgaatcg	7140
atagcgataa	ggatcccggt	atgggtgact	ctcagtacaa	tctgctctga	tgccgcatag	7200
ttaagccagc	cccgacacc	gccaacacc	gctgacgcgc	cctgacgggc	ttgtctgctc	7260
ccggcatccg	cttacagaca	agctgtgacc	gtctccggga	gctgcatgtg	tcagaggttt	7320
tcaccgctat	caccgaaacg	cgcgagacga	aaggccctcg	tgatacgcct	atctttatag	7380
gttaatgtca	tgataataat	ggtttcttag	acgtcagggtg	gcacttttcc	gggaaatgtg	7440
cgcggaaccc	ctatttgttt	atctttctaa	atacattcaa	atatgtatcc	gctcatgaga	7500
caataaccct	gataaatgct	tcaataatat	tgaaaagga	agagtatgag	tattcaacat	7560
ttccgtgtcg	cccttatcc	cttttttgcc	gcattttgcc	ttctgtttt	tgctcaccca	7620
gaaacgctgg	tgaaagtaaa	agatgctgaa	gatcagttgg	gtgcacgagt	gggttacatc	7680
gaactggatc	tcaacagcgg	taagatcctt	gagagttttc	gccccgaaga	acgttttcca	7740
atgatgagca	cttttaaagt	tctgctatgt	ggcgcggtat	tatcccgtat	tgacgcccgg	7800
caagagcaac	tccgtcgcgg	catacactat	tctcagaatg	acttggttga	gtactacca	7860
gtcacagaaa	agcatcttac	ggatggcatg	acagtaagag	aattatgcag	tgctgccata	7920
accatgagtg	ataaactgct	ggccaactta	cttctgacaa	cgatcggagg	accgaaggag	7980

-continued

ctaaccgctt	ttttgcacaa	catgggggat	catgtaactc	gccttgatcg	ttgggaaccg	8040
gagctgaatg	aagccatacc	aaacgacgag	ctgacacca	cgatgcctgt	agcaatggca	8100
acaacgttgc	gcaaactatt	aactggcgaa	ctacttactc	tagcttcccc	gcaacaatta	8160
atagactgga	tggaggcggg	taaagttgca	ggaccacttc	tgcgctcggc	ccttccggct	8220
ggctggttta	ttgctgataa	atctggagcc	ggtgagcgtg	ggtctcggcg	tatcattgca	8280
gcactggggc	cagatggtaa	gccctcccgt	atcgtagtta	tctacacgac	ggggagttag	8340
gcaactatgg	atgaacgaaa	tagacagatc	gctgagatag	gtgcctcact	gattaagcat	8400
tggtaaactgt	cagaccaagt	ttactcatat	atactttaga	ttgatttaa	acttcatttt	8460
taatttaaaa	ggatctaggt	gaagatcctt	tttgataatc	tcatgaccaa	aatcccttaa	8520
cgtgagtttt	cgttccactg	agcgtcagac	cccgtagaaa	agatcaaagg	atcttcttga	8580
gacccctttt	ttctgcgctg	aatctgctgc	ttgcaaaaa	aaaaaccacc	gctaccagcg	8640
gtggtttggt	tgccggatca	agagctacca	actctttttc	cgaaggtaac	tggttccagc	8700
agagcgcaga	taccaaatac	tgtccttcta	gtgtagccgt	agttaggcca	ccacttcaag	8760
aactctgtag	caccgcctac	atacctcgtc	ctgctaatac	tgttaccagt	ggctgctgcc	8820
agtggcgata	agtcgtgtct	taccgggttg	gactcaagac	gatagttacc	ggataaggcg	8880
cagcggctgg	gctgaacggg	gggttcgtgc	acacagccca	gcttgagcgc	aacgacctac	8940
accgaactga	gatacctaca	gcgtgagcta	tgagaaagcg	ccacgcttcc	cgaagggaga	9000
aaggcggaca	ggatccgggt	aagcggcagg	gtcggaaacg	gagagcgcac	gagggagctt	9060
ccagggggaa	acgcctggta	tctttatagt	cctgtcgggt	ttcgccacct	ctgacttgag	9120
cgctgatttt	tgtgatgctc	gtcagggggg	cggagcctat	ggaaaaacgc	cagcaacggc	9180
gcctttttac	ggttcctggc	cttttgctgg	ccttttgctc	acatggctcg	acagatccat	9240
ttaaattttc	accgtcatca	ccgaaacggc	cagggcagct	gtggaatgtg	tgtcagttag	9300
gggtgtgaaa	gtccccaggc	tccccagcag	gcagaagtat	gcaaagcatg	catctcaatt	9360
agtcagcaac	caggtgtgga	aagtccccag	gctccccagc	aggcagaagt	atgcaaagca	9420
tgcattctca	ttagttagca	accatagtcc	cgccccctaa	tccgccccat	ccgccccctaa	9480
ctccgcccag	ttccgcccac	tctccgcccc	atggctgact	aatttttttt	atztatgcag	9540
aggccgaggc	cgctcggccc	tctgagctat	tccagaagta	gtgaggaggc	ttttttggag	9600
gcctaggctt	ttgcaaaaag	ctttatcccc	gctgccatca	tggttcgacc	attgaactgc	9660
atcgtcgcgc	tgtcccaaga	tatggggatt	ggcaagaacg	gagacctacc	ctggcctccg	9720
ctcaggaacg	agttcaagta	cttccaaaga	atgaccacaa	cctcttcagt	ggaaggtaaa	9780
cagaatctgg	tgattatggg	taggaaaacc	tggttctcca	ttctgagaa	gaatcgacct	9840
ttaaaggaca	gaattaatat	agttctcagt	agagaactca	aagaaccacc	acgaggagct	9900
cattttcttg	ccaaaagttt	ggatgatgcc	ttaagactta	ttgaacaacc	ggaattggca	9960
agtaaagtag	acatggtttg	gatagtcgga	ggcagttctg	tttaccagga	agccatgaat	10020
caaccaggcc	acctcagact	ctttgtgaca	aggatcatgc	aggaatttga	aagtgacacg	10080
tttttcccag	aaattgattt	ggggaatat	aaacttctcc	cagaataccc	aggcgtcctc	10140
tctgaggtcc	aggaggaaaa	aggcatcaag	tataagtttg	aagtctacga	gaagaaagac	10200
taacaggaag	atgctttcaa	gttctctgct	ccctcctaa	agctatgcat	ttttataaga	10260
ccatgggact	tttgctggct	ttagatcttt	gtgaaggaa	cttacttctg	tggtgtgaca	10320
taattggaca	aactacctac	agagatttaa	agctctaagg	taaatataaa	atttttaagt	10380

-continued

```

gtataatgtg ttaaactact gattctaatt gtttgtgtat tttagattcc aacctatgga 10440
actgatgaat gggagcagtg gtggaatgcc tttaatgagg aaaacctgtt ttgctcagaa 10500
gaaatgccat ctagtgatga tgaggctact gctgactctc aacattctac tcctccaaaa 10560
aagaagagaa aggtagaaga cccaaggac ttccttcag aattgctaag ttttttgagt 10620
catgctgtgt ttagtaatag aactcttgct tgctttgcta tttacaccac aaaggaaaaa 10680
gctgcactgc tatacaagaa aattatggaa aaatattctg taacctttat aagtaggcat 10740
aacagttata atcataacat actgtttttt cttactccac acaggcatag agtgtctgct 10800
attaataact atgctcaaaa attgtgtacc tttagctttt taatttgtaa aggggttaat 10860
aaggaatatt tgatgtatag tgcttgact agagatcata atcagccata ccacatttgt 10920
agaggtttta cttgctttaa aaaacctccc acacctccc ctgaacctga aacataaaat 10980
gaatgcaatt gttgttgta acttgtttat tgcagcttat aatggttaca aataaagcaa 11040
tagcatcaca aatttcacaa ataaagcatt ttttctactg cattctagtt gtggtttgaa 11100
ttcggatct 11109

```

```

<210> SEQ ID NO 2
<211> LENGTH: 59
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: MCS site I; chemically synthesized

```

```

<400> SEQUENCE: 2

```

```

ctagggccca cgggtgaccg ttaaacacg tgatatccgg acaattgtcg gcgcgccgg 59

```

```

<210> SEQ ID NO 3
<211> LENGTH: 46
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Primer; chemically synthesized

```

```

<400> SEQUENCE: 3

```

```

gggcactacg tgccgcggat ttaaattgcg cgcgatatgg tgcact 46

```

```

<210> SEQ ID NO 4
<211> LENGTH: 38
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Primer; chemically synthesized

```

```

<400> SEQUENCE: 4

```

```

gggcacgtag tgtttattag gggagcagag aacttgaa 38

```

```

<210> SEQ ID NO 5
<211> LENGTH: 564
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: DHFR wildtype;

```

```

<400> SEQUENCE: 5

```

```

atggttogac cattgaactg catcgtcgcc gtgtcccaag atatggggat tggcaagaac 60
ggagacctac cctggcctcc gctcaggaac gagttcaagt acttccaaag aatgaccaca 120
acctcttcag tggaaggtaa acagaatctg gtgattatgg gtaggaaaac ctggttctcc 180

```


-continued

```

attcctgaga agaatcgacc tttaaaggac agaattaata tagttctcag tagagaactc 240
aaagaaccac cacgaggagc tcattttctt gccaaaagtt tggatgatgc cttaagactt 300
attgaacaac cggaattggc aagtaaagta gacatggttt ggatagtcgg aggcagttct 360
gtttaccagg aagccatgaa tcaaccaggc cacctcagac tctttgtgac aaggatcatg 420
caggaatttg aaagtgacac gtttttccca gaaattgatt tggggaaata taaacttctc 480
ccagaatacc caggcgtcct ctctgaggtc caggaggaaa aaggcatcaa gtataagttt 540
gaagtctacg agaagaaaga ctaa 564

```

```

<210> SEQ ID NO 6
<211> LENGTH: 564
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: DHFR mutant;

```

```

<400> SEQUENCE: 6

```

```

atggttcgac cattgaactg catcgtcgcc gtgtcccaaa atatggggat tggcaagaac 60
ggagaccgac cctggcctcc gctcaggaac gagttcaagt acttccaaag aatgaccaca 120
acctcttcag tggaaggtaa acagaatctg gtgattatgg gtaggaaaac ctggttctcc 180
attcctgaga agaatcgacc tttaaaggac agaattaata tagttctcag tagagaactc 240
aaagaaccac cacgaggagc tcattttctt gccaaaagtt tggatgatgc cttaagactt 300
attgaacaac cggaattggc aagtaaagta gacatggttt ggatagtcgg aggcagttct 360
gtttaccagg aagccatgaa tcaaccaggc cacctcagac tctttgtgac aaggatcatg 420
caggaatttg aaagtgacac gtttttccca gaaattgatt tggggaaata taaacttctc 480
ccagaatacc caggcgtcct ctctgaggtc caggaggaaa aaggcatcaa gtataagttt 540
gaagtctacg agaagaaaga ctaa 564

```

```

<210> SEQ ID NO 7
<211> LENGTH: 795
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Neomycin resistance gene;

```

```

<400> SEQUENCE: 7

```

```

atgattgaac aagatggatt gcacgcaggt tctccggccg cttgggtgga gaggctattc 60
ggctatgact gggcacaaca gacaatcggc tgetctgatg ccgccgtgtt ccggtgtca 120
gcgagggggc gcccggttct ttttgtcaag accgacctgt ccggtgccct gaatgaactg 180
caggacgagg cagcgcggct atcgtggctg gccacgacgg gcgttccttg cgcagctgtg 240
ctcgacgttg tcaactgaagc ggaaggggac tggctgctat tgggcgaagt gccggggcag 300
gatctcctgt catctcacct tgctcctgcc gagaaagtat ccatcatggc tgatgcaatg 360
cggcggctgc atacgttga tccggctacc tgcccattcg accaccaagc gaaacatcgc 420
atcgagcgag cacgtactcg gatggaagcc ggtcttgtcg atcaggatga tctggacgaa 480
gagcatcagg ggctcgcgcc agccgaactg ttcgccaggc tcaaggcgcg catgcccgac 540
ggcagggatc tcgtcgtgac ccatggcgat gctgcttgc cgaatatcat ggtggaaaat 600
ggccgctttt ctggattcat cgactgtggc cggctgggtg tggcggaccg ctatcaggac 660
atagcgttgg ctaccctgga tattgctgaa gagcttggcg gcgaatgggc tgaccgcttc 720
ctcgtgcttt acggtatcgc cgctcccgat tcgcagcgcg tcgccttcta tcgccttctt 780

```

-continued

gacgagttct tctga 795

<210> SEQ ID NO 8
 <211> LENGTH: 743
 <212> TYPE: DNA
 <213> ORGANISM: Artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: CMV promoter;

<400> SEQUENCE: 8

tcaatattgg ccattagcca tattattcat tggttatata gcataaatca atattggcta 60
 ttggccattg catacgttgt atctatatca taatatgtac atttatattg gctcatgtcc 120
 aatatgaccg ccatgttggc attgattatt gactagttat taatagtaat caattacggg 180
 gtcattagtt catagcccat atatggagtt ccgcgttaca taacttacgg taaatggccc 240
 gcctggctga ccgcccacg acccccgccc attgacgtca ataatgacgt atgttcccat 300
 agtaacgcca atagggactt tccattgacg tcaatgggtg gagtatttac ggtaaactgc 360
 ccacttggca gtacatcaag tgtatcatat gccaaagtacg ccccctattg acgtcaatga 420
 cggtaaatgg cccgcctggc attatgcccga gtacatgacc ttatgggact ttctacttg 480
 gcagtacatc tacgtattag tcatcgctat taccatgggtg atgcggtttt ggcagtacat 540
 caatgggctg ggatagcggc ttgactcacg gggatttcca agtctccacc ccattgacgt 600
 caatgggagt ttgttttggc accaaaatca acgggacttt ccaaaatgac gtaacaactc 660
 cgccccattg acgcaaatgg gcggtaggcg tgtacgggtg gaggtctata taagcagagc 720
 tcgttttagtg aaccgtcaga tcg 743

<210> SEQ ID NO 9
 <211> LENGTH: 419
 <212> TYPE: DNA
 <213> ORGANISM: Artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: SV40 Promoter;

<400> SEQUENCE: 9

gcgacgacc atggcctgaa ataacctctg aaagaggaac ttggtaggt accttctgag 60
 gcggaaagaa ccagctgtgg aatgtgtgac agttaggggtg tggaaagtcc ccaggctccc 120
 cagcaggcag aagtatgcaa agcatgcatc tcaattagtc agcaaccagg tgtggaaagt 180
 ccccaggctc cccagcaggc agaagtatgc aaagcatgca tctcaattag tcagcaacca 240
 tagtcccgcc cctaactccg cccatcccgc ccctaactcc gccagttcc gccattctc 300
 cgccccatgg ctgactaatt ttttttattt atgcagaggc cgaggccgcc tcggcctctg 360
 agctattcca gaagtagtga ggaggctttt ttggaggcct aggccttttgc aaaaagctt 419

<210> SEQ ID NO 10
 <211> LENGTH: 222
 <212> TYPE: DNA
 <213> ORGANISM: Artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: SV40 Poly A Site;

<400> SEQUENCE: 10

cagacatgat aagatacatt gatgagtttg gacaaaccac aactagaatg cagtgaaaaa 60
 aatgctttat ttgtgaaatt tgtgatgcta ttgctttatt tgtaaccatt ataagctgca 120
 ataaacaagt taacaacaac aattgcattc attttatggt tcaggttcag ggggagatgt 180

-continued

 gggaggtttt ttaaagcaag taaaacctct acaaatgtgg ta 222

<210> SEQ ID NO 11
 <211> LENGTH: 200
 <212> TYPE: DNA
 <213> ORGANISM: Artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: RK intron;

<400> SEQUENCE: 11

ttggaacgcg gattccccgt gccaaagatg acgtaagtac cgcctataga gtctataggc 60
 ccacccccctt ggcttcgcta gaacgcggtt acaattaata cataacctta tgtatcatac 120
 acatacgatt taggtgacac tatagaataa catccacttt gcctttctct ccacaggtgt 180
 ccaactcccag gtccaactgc 200

<210> SEQ ID NO 12
 <211> LENGTH: 942
 <212> TYPE: DNA
 <213> ORGANISM: Artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: DHFR mutant including intron;
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <222> LOCATION: (565)..(942)
 <223> OTHER INFORMATION: intron

<400> SEQUENCE: 12

atggttcgac cattgaactg catcgtcgcc gtgtcccaaa atatggggat tggcaagaac 60
 ggagaccgac cctggcctcc gctcaggaac gagttcaagt acttccaaag aatgaccaca 120
 acctcttcag tggaaagtaa acagaatctg gtgattatgg gtaggaaaac ctggttctcc 180
 attcctgaga agaatcgacc tttaaaggac agaattaata tagttctcag tagagaactc 240
 aaagaaccac cacgaggagc tcattttctt gccaaaagtt tggatgatgc cttaaagactt 300
 attgaacaac cggaattggc aagtaaagta gacatggttt ggatagtcgg aggcagttct 360
 gtttaccagg aagccatgaa tcaaccaggc cacctcagac tctttgtgac aaggatcatg 420
 caggaatttg aaagtgacac gtttttccca gaaattgatt tggggaaata taaacttctc 480
 ccagaatacc caggcgtcct ctctgaggtc caggaggaaa aaggcatcaa gtataagttt 540
 gaagtctacg agaagaaaga ctaacaggaa gatgctttca agttctctgc tccccctcta 600
 aagctatgca tttttataag accatggggg atgctcgatc ccctcgcgag ttggttcagc 660
 tgctgctga ggctggacga cctcgcggag ttctaccggc agtgcaaate cgteggcatc 720
 caggaaacca gcagcggcta tccgcgcate catgccccg aactgcagga gtggggaggc 780
 acgatggccg ctttggctcg gatctttgtg aaggaacctt acttctgtgg tgtgacataa 840
 ttggacaaac tacctacaga gatttaaagc tctaaggtaa atataaaatt ttaagtgtgta 900
 taatgtgtta aactactgat tctaattggt tgtgtatatt ag 942

<210> SEQ ID NO 13
 <211> LENGTH: 49
 <212> TYPE: DNA
 <213> ORGANISM: Artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic poly A site; chemically synthesized

<400> SEQUENCE: 13

aataaaatat ctttattttc attacatctg tgtgttggtt ttttgtgtg 49

-continued

```

<210> SEQ ID NO 14
<211> LENGTH: 861
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Beta lactamase antibiotic resistance gene;

<400> SEQUENCE: 14

atgagtattc aacatttccg tgcgcctt attccctttt ttgcggcatt ttgccttctt      60
gtttttgctc acccagaaac gctggtgaaa gtaaaagatg ctgaagatca gttgggtgca    120
cgagtgggtt acatcgaact ggatctcaac agcggtaaga tccttgagag ttttcgcccc    180
gaagaacggt ttccaatgat gagcactttt aaagttctgc tatgtggcgc ggtattatcc    240
cgtattgacg cggggcaaga gcaactcggg cggcgatac actatttctca gaatgacttg    300
gttgagtact caccagtcac agaaaagcat cttacggatg gcatgacagt aagagaatta    360
tgcagtgctg ccataaccat gagtgataac actgcggcca acttacttct gacaacgatc    420
ggaggaccga aggagctaac cgcttttttg cacaacatgg gggatcatgt aactcgcctt    480
gatcgttggg aaccggagct gaatgaagcc ataccaaacy acgagcgtga caccacgatg    540
cctgtagcaa tggcaacaac gttgcgcaa ctattaactg gcgaactact tactctagct    600
tcccggcaac aattaataga ctggatggag gcggataaag ttgcaggacc acttctgcgc    660
tcggcccttc cggctggctg gtttattgct gataaatctg gagccgggtg gcgtgggtct    720
cgcggtatca ttgcagcact ggggccagat ggtaagccct cccgtatcgt agttatctac    780
acgacgggga gtcaggcaac tatggatgaa cgaaatagac agatcgctga gataggtgcc    840
tactgatta agcattggta a                                     861

```

```

<210> SEQ ID NO 15
<211> LENGTH: 39
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: MCS site II; chemically synthesized

<400> SEQUENCE: 15

ctagcctcga gaattcacgc gtggtacctc tagagtcca                                     39

```

```

<210> SEQ ID NO 16
<211> LENGTH: 9210
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Vector sequence pBW165;
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1)..(743)
<223> OTHER INFORMATION: CMV prom/enh
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (825)..(1024)
<223> OTHER INFORMATION: RK-intron
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (857)..(1000)
<223> OTHER INFORMATION: RK-intron region which is spliced out upon
expression
<220> FEATURE:
<221> NAME/KEY: variation
<222> LOCATION: (1053)..(1054)
<223> OTHER INFORMATION: insertion of mAB LC or functional fragment
thereof
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1101)..(1322)

```

-continued

<223> OTHER INFORMATION: SV40polyA
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <222> LOCATION: (1653)..(2395)
 <223> OTHER INFORMATION: CMV prom/enh
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <222> LOCATION: (2477)..(2676)
 <223> OTHER INFORMATION: RK-intron
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <222> LOCATION: (2509)..(2652)
 <223> OTHER INFORMATION: RK-intron region which is spliced upon
 expression
 <220> FEATURE:
 <221> NAME/KEY: variation
 <222> LOCATION: (2750)..(2751)
 <223> OTHER INFORMATION: insertion of mAB HC or functional fragment
 thereof
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <222> LOCATION: (2817)..(3038)
 <223> OTHER INFORMATION: SV40polyA
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <222> LOCATION: (3133)..(3588)
 <223> OTHER INFORMATION: f1 region
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <222> LOCATION: (3652)..(4070)
 <223> OTHER INFORMATION: SV40 prom
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <222> LOCATION: (3968)..(4033)
 <223> OTHER INFORMATION: minimum origin of replication
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <222> LOCATION: (4115)..(4909)
 <223> OTHER INFORMATION: Neomycin phosphotransferase gene
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <222> LOCATION: (4973)..(5021)
 <223> OTHER INFORMATION: synthetic polyA
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <222> LOCATION: (5432)..(6292)
 <223> OTHER INFORMATION: Beta lactamase antibiotic resistance
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <222> LOCATION: (7170)..(7508)
 <223> OTHER INFORMATION: SV40 prom
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <222> LOCATION: (7585)..(8148)
 <223> OTHER INFORMATION: DHFR mutant
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <222> LOCATION: (8149)..(8526)
 <223> OTHER INFORMATION: DHFR mutant intron
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <222> LOCATION: (9010)..(9205)
 <223> OTHER INFORMATION: SV40 polyA

<400> SEQUENCE: 16

tcaatattgg ccattagcca tattattcat tggttatata gcataaatca atattggcta	60
ttggccattg catacgttgt atctatatca taatatgtac atttatattg gctcatgtcc	120
aatatgaccg ccatgttggc attgattatt gactagttat taatagtaat caattacggg	180
gtcattagtt catagcccat atatggagtt ccgcgttaca taacttacgg taaatggccc	240
gcctggctga ccgcccaacg acccccgccc attgacgtca ataatgacgt atgttcccat	300
agtaacgcca atagggactt tccattgacg tcaatgggtg gagtatttac ggtaaactgc	360
ccacttgcca gtacatcaag tgtatcatat gccaaagtacg cccctattg acgtcaatga	420

-continued

cggtaaatgg	cccgctggc	attatgccc	gtacatgacc	ttatgggact	ttcctacttg	480
gcagtacatc	tacgtattag	tcatcgctat	taccatggtg	atgcggtttt	ggcagtacat	540
caatgggctg	ggatagcgg	ttgactcacg	gggatttcca	agtctccacc	ccattgacgt	600
caatgggagt	ttgttttggc	acaaaaatca	acgggacttt	ccaaaatgtc	gtaacaactc	660
cgccccattg	acgcaaatgg	gcggtaggcg	tgtacgggtg	gaggtctata	taagcagagc	720
tcgttttagtg	aaccgtcaga	tcgcctggag	acgccatcca	cgctgttttg	acctccatag	780
aagacaccgg	gaccgatcca	gcctccggcg	ccgggaacgg	tgcattggaa	cgcggtattc	840
ccgtgccaa	agtgacgtaa	gtaccgccta	tagagtctat	aggcccacc	ccttggttcc	900
gttagaacgc	ggctacaatt	aatacataac	cttatgtatc	atacacatac	gatttaggtg	960
acactataga	ataacatcca	ctttgccttt	ctctccacag	gtgtccactc	ccaggtccaa	1020
ctgcacctcg	gttctatcga	aaacgcgtcc	accgtcgacc	cgggcgggccg	cttcccttta	1080
gtgagggtta	atgcttcgag	cagacatgat	aagatacatt	gatgagtttg	gacaaaccac	1140
aactagaatg	cagtgaaaaa	aatgctttat	ttgtgaaatt	tgtgatgcta	ttgctttatt	1200
tgtaacatt	ataagctgca	ataaacaagt	taacaacaac	aattgcattc	attttatggt	1260
tcaggttcag	ggggagatgt	gggaggtttt	ttaaagcaag	taaaacctct	acaaatgtgg	1320
taaaatccga	taaggatcga	tccgggctgg	cgtaatagcg	aagaggcccg	caccgatcgc	1380
ccttcccaac	agttgctcag	cctgaatggc	gaatggacgc	gccctgtagc	ggcgcattaa	1440
gcgcgggcgg	tgtgggtggt	acgcgcagcg	tgaccgctac	acttgccagc	gccctagcgc	1500
ccgctccttt	cgctttcttc	ccttcctttc	tcgccacggt	cgccggcttt	ccccgtcaag	1560
ctctaaatcg	ggggctccct	ttagggttcc	gatttagagc	tttacggcac	ctcgaccgca	1620
aaaaacttga	tttgggtgat	ggttcacgat	cttcaatatt	ggccattagc	catattattc	1680
attggttata	tagcataaat	caatattggc	tattggccat	tgcatacgtt	gtatctatat	1740
cataatatgt	acatttatat	tggctcatgt	ccaatatgac	cgccatggtg	gcattgatta	1800
ttgactagtt	attaatagta	atcaattacg	gggtcattag	ttcatagccc	atatatggag	1860
ttccgcgtta	cataacttac	ggtaaatggc	ccgcctggct	gaccgcccac	cgacccccgc	1920
ccattgacgt	caataatgac	gtatgttccc	atagtaacgc	caatagggac	tttccattga	1980
cgccaatggg	tggagtattt	acggtaaact	gccacttgg	cagtacatca	agtgtatcat	2040
atgccaagta	cgccccctat	tgacgtcaat	gacggtaaat	ggccccgctg	gcattatgcc	2100
cagtacatga	ccttatggga	ctttcctact	tggcagtaca	tctacgtatt	agtcacgct	2160
attaccatgg	tgatgctggt	ttggcagtac	atcaatgggc	gtggatagcg	gtttgactca	2220
cggggatttc	caagtctcca	ccccattgac	gtcaatggga	gtttgttttg	gcacccaaat	2280
caacgggact	ttccaaaatg	tcgtaacaac	tccgccccat	tgacgcaaat	ggcggttagg	2340
cgtgtacggg	gggaggctca	tataagcaga	gctcgtttag	tgaaccgtca	gatcgctggg	2400
agacgccatc	cacgctgttt	tgacctccat	agaagacacc	gggaccgatc	cagcctccgc	2460
ggccgggaac	ggtgcattgg	aacgcggatt	ccccgtgcca	agagtgacgt	aagtaccgcc	2520
tatagagtct	ataggcccac	ccccttggct	tcgttagaac	gcggtacaaa	ttaatacata	2580
accttatgta	tcatacacat	acgatttagg	tgacactata	gaataacatc	cactttgcct	2640
ttctctccac	aggtgtccac	tcccaggctc	aactgcacct	cggttctatc	gcgattgaat	2700
taattccccg	gggatcctct	agggtgaccg	tttaaaacac	cggtgccacc	ggcgctgggt	2760

-continued

acctctagag	tcgacccggg	cggccgcttc	cctttagtga	gggttaatgc	ttcgagcaga	2820
catgataaga	tacattgatg	agtttggaca	aaccacaact	agaatgcagt	gaaaaaatg	2880
ctttatttgt	gaaatttgtg	atgctattgc	tttatttcta	accattataa	gctgcaataa	2940
acaagttaac	aacaacaatt	gcattcattt	tatgtttcag	gttcaggggg	agatgtggga	3000
ggttttttaa	agcaagtaaa	acctctacaa	atgtggtaaa	atccgataag	gatcgatccg	3060
ggctggcgta	atagcgaaga	ggcccgcacc	gatcgccctt	cccaacagtt	gcgcagcctg	3120
aatggcgaat	ggacgcgccc	tgtagcggcg	cattaagcgc	ggcgggtgtg	gtggttacgc	3180
gcagcgtgac	cgctacactt	gccagcgcct	tagcgcgcgc	tcctttcgct	ttcttcctt	3240
cctttctcgc	cacgttcgcc	ggctttcccc	gtcaagctct	aaatcggggg	ctccctttag	3300
ggttccgatt	tagagcttta	cggcacctcg	accgcaaaaa	acttgatttg	ggatgatggt	3360
cacgtagtgg	gccatcgccc	tgatagacgg	tttttcgccc	tttgacgttg	gagtccacgt	3420
tctttaatag	tggactcttg	ttccaaactg	gaacaacact	caaccctatc	tcggtctatt	3480
cttttgattt	ataagggatt	ttgccgattt	cggcctattg	gttaaaaaat	gagctgattt	3540
aacaaatatt	taacgcgaat	tttaacaaaa	tattaacggt	tacaatttcg	cctgatgcgg	3600
tattttctcc	ttacgcatct	gtgcgggtatt	tcacaccgca	tacgcggatc	tgcgcagcac	3660
catggcctga	aataacctct	gaaagaggaa	cttggttagg	taccttctga	ggcggaaaga	3720
accagctgtg	gaatgtgtgt	cagttagggt	gtggaaagtc	cccaggctcc	ccagcaggca	3780
gaagtatgca	aagcatgcat	ctcaattagt	cagcaaccag	gtgtggaaag	tccccaggct	3840
cccagcagg	cagaagtatg	caaagcatgc	atctcaatta	gtcagcaacc	atagtcccgc	3900
ccctaactcc	gcccattccc	cccctaactc	cgcccagttc	cgcccattct	ccgcccctg	3960
gctgactaat	tttttttatt	tatgcagagg	ccgaggccgc	ctcggcctct	gagctattcc	4020
agaagtagtg	aggaggcttt	tttggaggcc	taggcttttg	caaaaagctt	gattcttctg	4080
acacaacagt	ctcgaactta	aggctagagc	caccatgatt	gaacaagatg	gattgcacgc	4140
aggttctccg	gccgcttggg	tggagaggct	attcggctat	gactgggcac	aacagacaat	4200
cggctgctct	gatgccgccc	tgttccggct	gtcagcgcag	gggcgcccgg	ttctttttgt	4260
caagacogac	ctgtccggtg	ccctgaatga	actgcaggac	gaggcagcgc	ggctatcgtg	4320
gctggccacg	acgggcgctc	cttgcgcagc	tgtgctcgac	gttgtcactg	aagcgggaag	4380
ggactggctg	ctattgggcg	aagtgccggg	gcaggatctc	ctgtcatctc	accttgctcc	4440
tgccgagaaa	gtatccatca	tggctgatgc	aatgcggcgg	ctgcatacgc	ttgatccggc	4500
tacctgccc	ttcgaccacc	aagcgaacaa	tcgcatcgag	cgagcacgta	ctcggatgga	4560
agccggctct	gtcgatcagg	atgatctgga	cgaagagcat	caggggctcg	cgccagccga	4620
actgttcgcc	aggctcaagg	cgcgcgatgc	cgacggcgag	gatctcgtcg	tgacctatgg	4680
cgatgcctgc	ttgccgaata	tcattggtgga	aaatggcgcg	ttttctggat	tcacgcactg	4740
tggccggctg	gggtgtggcg	accgctatca	ggacatagcg	ttggctacct	gtgatattgc	4800
tgaagagctt	ggcggcgaat	gggctgaccg	cttcctcgtg	ctttacggta	tcgcccctcc	4860
cgattcgcag	cgcatcgctt	tctatcgctt	tcttgacgag	ttcttctgag	cgggactctg	4920
gggttcgaaa	tgaccgacca	agcgcgcgcc	aacctgccat	cacgatggcc	gcaataaaat	4980
atctttatct	tcattacatc	tgtgtgttgg	ttttttgtgt	gaatcgatag	cgataaggat	5040
ccgcgtatgg	tgcactctca	gtacaatctg	ctctgatgcc	gcatagttaa	gccagccccg	5100
acaccgcca	acaccgctg	acgcgccttg	acgggcttgt	ctgctcccgg	catccgctta	5160

-continued

cagacaagct	gtgaccgtct	ccgggagctg	catgtgtcag	aggttttcac	cgatcacc	5220
gaaacgcg	agacgaaagg	gcctcgtgat	acgcctat	ttatagg	atgtcatgat	5280
aataatggtt	tcttagacgt	caggtggcac	ttttcgggga	aatgtgcg	gaaccctat	5340
ttgtttat	ttctaaatac	attcaaata	gtatccgctc	atgagacaat	aaccctgata	5400
aatgcttcaa	taatattgaa	aaaggaagag	tatgagtatt	caacatttcc	gtgtcgcct	5460
tattcccttt	tttgcggcat	tttgccttcc	tgtttttgct	caccagaaa	cgctggtgaa	5520
agtaaaagat	gctgaagatc	agttgggtgc	acgagtgggt	tacatcgaac	tggatctcaa	5580
cagcggtaag	atccttgaga	gttttcgccc	cgaagaacgt	ttccaatga	tgagcacttt	5640
taaagtctg	ctatgtggcg	cggtattatc	ccgtattgac	gccgggcaag	agcaactcgg	5700
tcgccgata	cactattctc	agaatgactt	ggttgagtac	tcaccagtca	cagaaaagca	5760
tcttacggat	ggcatgacag	taagagaatt	atgcagtgct	gccataacca	tgagtgataa	5820
cactgcggcc	aacttacttc	tgacaacgat	cggaggaccg	aaggagctaa	ccgctttttt	5880
gcacaacatg	gggatcatg	taactcgcct	tgatcgttgg	gaaccggagc	tgaatgaagc	5940
cataccaa	gacgagcgtg	acaccacgat	gcctgtagca	atggcaaca	cgttgcgcaa	6000
actattaact	ggcgaactac	ttactctagc	ttcccggcaa	caattaatag	actggatgga	6060
ggcggataaa	ggtgcaggac	cacttctgcg	ctcggccctt	ccggctggct	ggtttattgc	6120
tgataaatct	ggagccggtg	agcgtgggtc	tcgcggtatc	attgcagcac	tggggcca	6180
tggtaaagccc	tcccgtatcg	tagttatcta	cacgacgggg	agtcaggcaa	ctatggatga	6240
acgaaataga	cagatcgtg	agataggtgc	ctcactgatt	aagcattggt	aactgtcaga	6300
ccaagtttac	tcatatatac	tttagattga	tttaaaactt	cattttta	ttaaaaggat	6360
ctaggtgaag	atcctttttg	ataatctcat	gacaaaatc	ccttaacgtg	agttttcgtt	6420
ccactgagcg	tcagaccccg	tagaaaagat	caaaggatct	tcttgagatc	ctttttttct	6480
gcgcgtaatc	tgctgcttgc	aaacaaaaaa	accaccgcta	ccagcgggtg	tttgtttgcc	6540
ggatcaagag	ctaccaactc	tttttcgaa	ggtaactggc	ttcagcagag	cgcagatacc	6600
aaatactgtc	cttctagtgt	agccgtagtt	aggccaccac	ttcaagaact	ctgtagcacc	6660
gcctacatac	ctcgtcttgc	taatcctggt	accagtggct	gctgccagtg	gcgataagtc	6720
gtgtcttacc	gggttgact	caagacgata	gttaccggat	aaggcgcagc	ggtcgggctg	6780
aacggggggg	tcgtgcacac	agcccagctt	ggagcgaacg	acctacaccg	aactgagata	6840
cctacagcgt	gagctatgag	aaagcggcac	gcttcccga	gggagaaagg	cggacaggta	6900
tccggtaa	ggcagggtcg	gaacaggaga	gcgcacgagg	gagcttccag	ggggaaacgc	6960
ctggatctt	tatagtcctg	tcgggtttcg	ccacctctga	cttgagcgtc	gattttttgtg	7020
atgctcgtca	ggggggcgga	gcctatggaa	aaacgccagc	aacgcggcct	ttttacggtt	7080
cctggccttt	tgctggcctt	ttgctcacat	ggctcgacag	atccatttaa	attttcaccg	7140
tcataccga	aacgcgcgag	gcagctgtgg	aatgtgtgtc	agttagggtg	tggaaagtcc	7200
ccaggctccc	cagcaggcag	aagtatgcaa	agcatgcatc	tcaattagtc	agcaaccagg	7260
tgtggaaagt	ccccaggctc	cccagcaggc	agaagtatgc	aaagcatgca	tctcaattag	7320
tcagcaacca	tagtcccgc	cctaactccg	ccatcccgc	ccctaactcc	gcccagttcc	7380
gcccattctc	cgcccattgg	ctgactaatt	ttttttat	atgcagaggc	cgaggccgcc	7440
tcggcctctg	agctattcca	gaagtatgga	ggaggctttt	ttggaggcct	aggcttttgc	7500

-continued

aaaaagctaa ttcgagctcg gtacccccaa acttgacggc aatcctagcg tgaaggctgg	7560
taggatttta tccccgctgc catcatgggt cgaccattga actgcatcgt cgccgtgtcc	7620
caaaatattg ggattggcaa gaacggagac cgaccctggc ctccgctcag gaacgagttc	7680
aagtacttcc aaagaatgac cacaacctct tcagtggaag gtaaacagaa tctggtgatt	7740
atgggtagga aaacctgggt ctccattcct gagaagaatc gacctttaa ggacagaatt	7800
aatatagttc tcagtagaga actcaaagaa ccaccacgag gagctcattt tcttgccaaa	7860
agtttgatg atgccttaag acttattgaa caaccggaat tggcaagtaa agtagacatg	7920
gtttgatag tcggaggcag ttctgtttac caggaagcca tgaatcaacc aggccacctc	7980
agactctttg tgacaaggat catgcaggaa tttgaaagt acacgttttt cccagaaatt	8040
gatttgaggga aatataaact tctcccagaa taccaggcg tcctctctga ggtccaggag	8100
gaaaaaggca tcaagtataa gtttgaagtc tacgagaaga aagactaaca ggaagatgct	8160
ttcaagttct ctgctcccct cctaaagcta tgcattttta taagaccatg ggggatgctc	8220
gatccccctc cgagttggtt cagctgctgc ctgaggctgg acgacctcgc ggagttctac	8280
cggcagtgca aatccgtcgg catccaggaa accagcagcg gctatccgcg catccatgcc	8340
cccgaactgc aggagtgggg aggcacgatg gccgctttgg tccggatctt tgtgaaggaa	8400
ccttacttct gtgggtgtgac ataattggac aaactaccta cagagattta aagctctaag	8460
gtaaataaa aatttttaag tgtataatgt gttaaactac tgattctaata tgtttgtgta	8520
ttttagattc caacctatgg aactgatgaa tgggagcagt ggtggaatgc ctttaatgag	8580
gaaaacctgt tttgctcaga agaaatgcc tctagtgatg atgaggctac tgctgactct	8640
caacattcta ctctccaaa aaagaagaga aaggtagaag accccaagga ctttccttca	8700
gaattgctaa gttttttgag tcatgctgtg ttagtaata gaactcttgc ttgctttgct	8760
atttacacca caaaggaaaa agctgcactg ctatacaaga aaattatgga aaaatattct	8820
gtaaccttta taagtaggca taacagttat aatcataaca tactgttttt tcttactcca	8880
cacaggcata gagtgtctgc tattaataac tatgctcaaa aattgtgtac ctttagcttt	8940
ttaatttgta aaggggttaa taaggaatat ttgatgtata gtgccttgac tagagatcat	9000
aatcagccat accacatttg tagaggtttt acttgcttta aaaaacctcc cacacctccc	9060
cctgaacctg aacataaaa tgaatgcaat tgttggtggt aacttgttta ttgcagctta	9120
taatggttac aaataaagca atagcatcac aaatttcaca aataaagcat ttttttact	9180
gcattctagt tgtggtttga attcggatct	9210

The invention claimed is:

[1. A vector nucleic acid suitable for expressing at least one polypeptide of interest in a mammalian cell, comprising

(a) at least one expression cassette (POI) suitable for expressing a polypeptide of interest;

(b) an expression cassette (MSM) comprising a mammalian selectable marker gene wherein said mammalian selectable marker gene is an antibiotic resistance gene; and

(c) an expression cassette (MASM) comprising a mammalian amplifiable, selectable marker gene;

wherein each said expression cassette (POI), (MSM), and (MASM) comprises at least one promoter or promoter/enhancer element, the expression cassette (POI) is

50 flanked 5' by the expression cassette (MASM), the expression cassette (MSM) is located 3' from the expression cassette (POI) and the expression cassettes (MASM), (POI), and (MSM) are arranged in the same 5' to 3' orientation

and wherein

the vector is circular and the expression cassette (MASM) is arranged 3' of the expression cassette (MSM) and wherein said circular vector comprises a unique linearization restriction site for linearizing the vector which is located between the expression cassettes (MSM) and (MASM);

or

wherein the vector is linearized via a unique linearization restriction site located between the expression cassettes (MSM) and (MASM); and

wherein the vector is selected from the group consisting of

(a) a circular or linear vector nucleic acid comprising the following genetic elements in the indicated arrangement, wherein the 5' to 3' direction is indicated by the →:

- I) Promoter of the (MASM) expression cassette (→)
- II) Gene encoding the mammalian amplifiable selectable marker of the (MASM) expression cassette (→)
- III) Intron of the (MASM) expression cassette (→)
- IV) PolyA site of the (MASM) expression cassette (→)
- V) Promoter of the (POI) expression cassette (→)
- VI) Intron of the (POI) expression cassette (→)
- VII) Polynucleotide encoding a polypeptide of interest, which is inserted in the (POI) expression cassette (→)
- VIII) PolyA site of the (POI) expression cassette (→)
- IX) Promoter of the (POI') expression cassette (→)
- X) Intron of the (POI') expression cassette (→)
- XI) Polynucleotide encoding an additional polypeptide of interest, which is inserted in the (POI') expression cassette (→)
- XII) PolyA site of the (POI') expression cassette (→)
- XIII) Promoter of the (MSM) expression cassette (→)
- XIV) Gene encoding the mammalian selectable marker of the (MSM) expression cassette (→)
- XV) PolyA site of the (MSM) expression cassette (→)
- XVI) PSM expression cassette (→) or (←)
- XVII) Linearization restriction site if the vector nucleic acid is circular; and

(b) a vector nucleic acid as shown as Seq. ID No. 1 or Seq. ID No. 16.]

2. A vector nucleic acid suitable for expressing at least one polypeptide of interest in a mammalian cell, comprising

- (a) at least one expression cassette (POI) suitable for expressing a polypeptide of interest;
- (b) an expression cassette (MSM) comprising a mammalian selectable marker gene wherein said mammalian selectable marker gene is an antibiotic resistance gene; and
- (c) an expression cassette (MASM) comprising a mammalian amplifiable, selectable marker gene;

wherein each said expression cassette (POI), (MSM), and (MASM) comprises at least one promoter or promoter/enhancer element, the expression cassette (POI) is flanked 5' by the expression cassette (MASM), the expression cassette (MSM) is located 3' from the expression cassette (POI) and the expression cassettes (MASM), (POI), and (MSM) are arranged in the same 5' to 3' orientation

and wherein

the vector is circular and the expression cassette (MASM) is arranged 3' of the expression cassette (MSM) and wherein said circular vector comprises a unique linearization restriction site for linearizing the vector which is located between the expression cassettes (MSM) and (MASM);

or

wherein the vector is linearized via a unique linearization restriction site located between the expression cassettes (MSM) and (MASM); and

wherein the vector is selected from the group consisting of (a) a circular or linear vector nucleic acid comprising the following genetic elements in the following order and indicated arrangement, wherein the 5' to 3' direction is indicated by the →:

- I) Promoter of the (MASM) expression cassette (→)
- II) Gene encoding the mammalian amplifiable selectable marker of the (MASM) expression cassette (→)
- III) Intron of the (MASM) expression cassette (→)
- IV) PolyA site of the (MASM) expression cassette (→)
- V) Promoter of the (POI) expression cassette (→)
- VI) Intron of the (POI) expression cassette (→)
- VII) Polynucleotide encoding a polypeptide of interest, which is inserted in the (POI) expression cassette (→)
- VIII) PolyA site of the (POI) expression cassette (→)
- IX) Promoter of the (POI') expression cassette (→)
- X) Intron of the (POI') expression cassette (→)
- XI) Polynucleotide encoding an additional polypeptide of interest, which is inserted in the (POI') expression cassette (→)
- XII) PolyA site of the (POI') expression cassette (→)
- XIII) Promoter of the (MSM) expression cassette (→)
- XIV) Gene encoding the mammalian selectable marker of the (MSM) expression cassette (→)
- XV) PolyA site of the (MSM) expression cassette (→)
- XVI) Prokaryotic selectable marker gene (PSM) expression cassette (→) or (←)
- XVII) Linearization restriction site if the vector nucleic acid is circular,

wherein the expression cassette POI' as indicated by elements IX to XII is optional; and

(b) a vector nucleic acid as shown as Seq. ID No. 1 or Seq. ID No. 16.

3. The vector nucleic acid of claim 2, wherein the expression cassette POI' as indicated by elements IX to XII is present.

4. The vector nucleic acid according to claim 2, wherein said expression cassette (MSM) comprises a gene encoding an enzymatically functional neomycin phosphotransferase and wherein said expression cassette (MASM) comprises a gene encoding an enzymatically functional dihydrofolate reductase (DHFR).

5. The vector nucleic acid according to claim 3 for expressing an immunoglobulin molecule comprising in each expression cassette (POI) and (POI') a polynucleotide encoding either a light or a heavy chain of an immunoglobulin molecule or functional fragments thereof, wherein each expression cassette (POI) and (POI') comprises one of said polynucleotides.

6. The vector nucleic acid according to claim 2, wherein said expression cassettes comprise an enhancer and/or an intron.

7. The vector nucleic acid according to claim 2, wherein the expression cassette (POI) and/or the expression cassette (POI') if present comprises a CMV promoter/enhancer and/or wherein the expression cassettes (MSM) and (MASM) comprise a SV40 promoter/enhancer or a SV40 promoter.

8. The vector nucleic acid according to claim 2, wherein the prokaryotic selectable marker gene (PSM) provides an antibiotic resistance, wherein said antibiotic is selected from the group consisting of ampicillin, kanamycin, tetracycline and chloramphenicol.

9. The vector nucleic acid according to claim 2, wherein the expression cassette (MASM) comprises a DHFR gene selected from the group consisting of wildtype DHFR, a DHFR having a reduced MTX sensitivity compared to wildtype DHFR and a DHFR having an enhanced MTX sensitivity compared to wildtype DHFR.

10. A mammalian host cell comprising a vector nucleic acid according to claim 2, wherein the vector is linearized via a unique linearization site located between the expres-

sion cassettes (MSM) and (MASM) and is stably integrated into the genome of the mammalian host cell.

11. The mammalian host cell according to claim 10, wherein said host cell is selected from the group consisting of COP, L, C127, Sp2/0, NS-0, NS-1, NIH3T3, PC12, PC12h, BHK and CHO, COS1, COS3, COS7, CV1, Vero, HeLa, HEK-293, retina-derived PER-C6, cells derived from diploid fibroblasts, myeloma cells and HepG2.

12. The mammalian host cell of claim 10, wherein the expression cassette POI' as indicated by elements IX to XII is present in the vector nucleic acid.

13. The mammalian host cell according to claim 10, wherein said vector nucleic acid comprises the expression cassette (MSM) comprising a gene encoding an enzymatically functional neomycin phosphotransferase and wherein said expression cassette (MASM) comprises a gene encoding an enzymatically functional dihydrofolate reductase (DHFR).

14. The mammalian host cell according to claim 12, for expressing an immunoglobulin molecule, the vector nucleic acid comprising in each expression cassette (POI) and (POI') a polynucleotide encoding either a light or a heavy chain of an immunoglobulin molecule or functional fragments thereof, wherein each expression cassette (POI) and (POI') comprises one of said polynucleotides.

15. The mammalian host cell according to claim 10, wherein said vector nucleic acid comprises expression cassettes comprising an enhancer and/or an intron.

16. The mammalian host cell according to claim 10, wherein expression cassette (POI) and/or expression cassette (POI') if present comprises a CMV promoter/enhancer and/or wherein the expression cassettes (MSM) and (MASM) comprise a SV40 promoter/enhancer or a SV40 promoter.

17. The mammalian host cell according to claim 15, wherein at least expression cassette (POI) comprises an intron which is arranged between the promoter and the start codon of the polynucleotide for expressing the polypeptide of interest.

18. The mammalian host cell according to claim 15, wherein the expression cassette (MASM) comprises an intron which is located 3' of the mammalian amplifiable selectable marker gene.

19. The mammalian host cell according to claim 10, wherein a prokaryotic selectable marker gene (PSM) of the vector nucleic acid provides an antibiotic resistance, wherein said antibiotic is selected from the group consisting of ampicillin, kanamycin, tetracycline and chloramphenicol.

20. The mammalian host cell according to claim 10, wherein the expression cassette (MASM) of the vector nucleic acid comprises a DHFR gene selected from the group consisting of wildtype DHFR, a DHFR having a reduced MTX sensitivity compared to wildtype DHFR and a DHFR having an enhanced MTX sensitivity compared to wildtype DHFR.

21. A linearized vector nucleic acid suitable for expressing at least one polypeptide of interest in a mammalian cell, comprising

- (a) at least one expression cassette (POI) suitable for expressing a polypeptide of interest;
- (b) an expression cassette (MSM) comprising a mammalian selectable marker gene wherein said mammalian selectable marker gene is an antibiotic resistance gene;
- (c) an expression cassette (MASM) comprising a mammalian amplifiable, selectable marker gene; and
- (d) an expression cassette (PSM) comprising a prokaryotic selectable marker gene;

wherein each said expression cassette (POI), (MSM), and (MASM) comprises at least one promoter or promoter/enhancer element, and the expression cassettes (MASM), (POI), and (MSM) are arranged in the same 5' to 3' orientation and wherein the expression cassettes (a) to (d) are arranged in the following order:

- I) Gene encoding the mammalian amplifiable selectable marker of the (MASM) expression cassette
- II) Polynucleotide encoding a polypeptide of interest, which is inserted in the (POI) expression cassette
- III) Gene encoding the mammalian selectable marker of the (MSM) expression cassette
- IV) Prokaryotic selectable marker gene (PSM) expression cassette.

22. The linearized vector nucleic acid according to claim 21, having one or more of the following characteristics:

- i) the expression cassette (MASM) comprises a gene encoding an enzymatically functional dihydrofolate reductase (DHFR);
- ii) the expression cassette (MSM) comprises a gene encoding an enzymatically functional neomycin phosphotransferase and wherein said expression cassette (MASM) comprises a gene encoding an enzymatically functional dihydrofolate reductase (DHFR);
- iii) the expression cassettes (POI), (MSM), and (MASM) comprise a promoter and/or transcription termination site;
- iv) the expression cassette for expressing the polypeptide of interest (POI) comprises a stronger promoter and/or enhancer than the expression cassettes for expressing the mammalian selectable markers;
- v) the expression cassettes (POI), (MSM), and (MASM) comprise an enhancer and/or an intron; and
- vi) the expression cassette (MASM) comprises an intron which is located 3' of the mammalian amplifiable selectable marker gene.

23. The linearized vector nucleic acid of claim 21, comprising at least one additional expression cassette (POI') for expressing an additional polypeptide of interest, wherein the additional expression cassette (POI') is located between the expression cassette (POI) and the expression cassette (MSM), and wherein the expression cassette (POI') is arranged in the same 5' to 3' orientation as the expression cassettes (POI) and (MSM).

24. The linearized vector nucleic acid of claim 23, comprising in each expression cassette (POI) and (POI') a polynucleotide encoding either a light or a heavy chain of an immunoglobulin molecule or functional fragments thereof, wherein each expression cassette (POI) and (POI') comprises one of said polynucleotides.

25. The linearized vector nucleic acid of claim 23, wherein the expression cassette (POI) and/or the expression cassette (POI') comprises a CMV promoter/enhancer and/or wherein the expression cassettes (MSM) and (MASM) comprise a SV40 promoter/enhancer or a SV40 promoter.

26. The linearized vector nucleic acid according to claim 21, having one or more of the following characteristics:

- i) the prokaryotic selectable marker gene provides an antibiotic resistance, wherein said antibiotic is selected from the group consisting of ampicillin, kanamycin, tetracycline, and chloramphenicol; and
- ii) the expression cassette (PSM) is arranged in the same 5' to 3' orientation as the expression cassettes (POI), (MSM), and (MASM).

27. A mammalian host cell comprising the linearized vector nucleic acid of claim 21.

28. *The mammalian host cell of claim 27, wherein the linearized vector nucleic acid is stably integrated into the genome of the mammalian host cell.*

* * * * *

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : RE49,347 E
APPLICATION NO. : 16/110010
DATED : December 27, 2022
INVENTOR(S) : Hans-Peter Knopf et al.

Page 1 of 1

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On the Title Page

Item (63) of the U.S. Applications section, delete “Continuation of application No. 12/808,798, filed as application No. PCT/EP2008/067947 on Dec. 18, 2008, now abandoned.” and insert --Reissue Continuation of U.S. Application No. 13/482,117, filed May 29, 2012, now U.S. Patent No. 9,422,574, which is a continuation of U.S. Application No. 12/808,798, filed June 17, 2010, now abandoned, which is a 35 U.S.C. 371 national stage filing of International Application No. PCT/EP2008/067947, filed December 18, 2008, which claims priority to European Patent Application 07150339.5, filed December 21, 2007. The contents of the aforementioned applications are hereby incorporated by reference.--

In the Specification

At Column 1, Line numbers 12-18, delete “This is a continuation of application Ser. No. 12/808,798 filed on Jun. 17, 2010, now abandoned, which is a National Stage of International Application NO. PCT/EP2008/067947 filed on Dec. 18, 2008, which claims priority under 35 U.S.C. §119 to EP Application Serial NO. 07150339.5 filed Dec. 21, 2007, each of which applications in its entirety is herein incorporated by reference.” and insert --This application is a Reissue Continuation of U.S. Application No. 13/482,117, filed May 29, 2012, now U.S. Patent No. 9,422,574, which is a continuation of U.S. Application No. 12/808,798, filed June 17, 2010, now abandoned, which is a 35 U.S.C. 371 national stage filing of International Application No. PCT/EP2008/067947, filed December 18, 2008, which claims priority to European Patent Application 07150339.5, filed December 21, 2007. The contents of the aforementioned applications are hereby incorporated by reference.--

At Column 1, Line 19, insert --The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on October 4, 2022, is named NV1-100USCNRERCE_SequenceListing_2022-10-04.txt and is 40037 bytes in size.--

Signed and Sealed this
Twenty-first Day of March, 2023
Katherine Kelly Vidal

Katherine Kelly Vidal
Director of the United States Patent and Trademark Office